Cyclic bisbenzyltetrahydroisoquinoline compounds and their preparation and use

Cyclic bisbenzyltetrahydroisoquinoline compounds address the limitations of existing SARS-CoV-2 treatments by enhancing antiviral efficacy and safety, while suppressing T cell differentiation to treat autoimmune and inflammatory diseases.

JP2024545167AInactive Publication Date: 2024-12-05SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024534490
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-10
Filing Date
2022-12-12
Publication Date
2024-12-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current antiviral drugs for SARS-CoV-2 have safety concerns and low efficacy, and there is a need for compounds that can suppress Th1 and Th17 cell differentiation to treat autoimmune diseases and inflammatory conditions.

Method used

Development of cyclic bisbenzyltetrahydroisoquinoline compounds, represented by formula I, which inhibit viral replication, suppress T cell differentiation, and have anti-inflammatory and antifibrotic effects, produced through methods involving alkylation, acylation, and ring-closing reactions.

Benefits of technology

The compounds demonstrate enhanced antiviral activity against SARS-CoV-2, lower cytotoxicity, and therapeutic index, effectively treating viral infections, autoimmune diseases, and inflammatory conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545167000001_ABST
    Figure 2024545167000001_ABST
Patent Text Reader

Abstract

The present invention provides a cyclic bisbenzyltetrahydroisoquinoline compound represented by formula (I), its pharma- ceutically acceptable salt, its enantiomer, its diastereomer, its racemate, its crystal hydrate and its solvate, wherein R1 and R2 are as defined in the specification. The present invention also provides a method for producing the compound and its use for producing an inhibitor that suppresses viruses, inflammation, fibrosis, abnormal T-cell differentiation and / or a drug for preventing and / or treating respiratory infections caused by viruses and associated diseases such as pneumonia, inflammation-associated diseases, fibrosis-associated diseases and autoimmune diseases. [Formula 1] JPEG2024545167000118.jpg72106
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of medicinal chemistry and chemical synthesis. In particular, the present invention relates to cyclic bisbenzyltetrahydroisoquinoline compounds and their preparation and use. [Background technology]

[0002] Most acute infectious diseases are viral infectious diseases, which have high incidence and mortality rates. Due to limited detection and diagnostic methods, the outbreak of new epidemics caused by new viruses is often sudden, random, and unpredictable. Once an outbreak occurs, it is likely to become a large-scale epidemic unless there is an effective treatment, posing a great threat to people's health, lives, and safety.

[0003] The novel coronavirus (SARS-CoV-2) is the seventh coronavirus discovered by humans so far, and Corona Virus Disease 2019 (COVID-19) is an acute infectious disease caused by this virus. The virus has now spread around the world, with the number of people infected and the number of deaths from it already exceeding that of SARS in 2003, posing a major threat to human health and the economic development of society.

[0004] At present, vaccines and antiviral drugs have been approved for sale against severe pneumonia caused by SARS-CoV-2 coronavirus, but their safety or efficacy is still not satisfactory. As of November 2021, many mutant strains of coronavirus have appeared, such as South African strain, Delta strain, Omicron strain, etc., which have become the main mutant viruses prevalent around the world. They have characteristics such as high viral load, strong transmissibility, stealth, and immune escape, and effective preventive and therapeutic measures and drugs are urgently needed in clinical practice. Therefore, it is of great social significance to develop antiviral drugs with low toxicity and high efficacy against SARS-CoV-2 coronavirus to meet the clinical needs of SARS-CoV-2 infected patients at home and abroad.

[0005] Cyclic bisbenzyltetrahydroisoquinoline compounds, including oxyacanthine, berbamine, tetrandrine, etc., which have good anti-pulmonary injury, anti-inflammatory, anti-fibrosis, and immunomodulatory effects, have attracted the attention of those skilled in the art. Since the outbreak of the new coronavirus pneumonia, the inventors have screened a large number of natural products for antiviral activity and found that cyclic bisbenzyltetrahydroisoquinoline alkaloids, such as berbamine, oxyacanthine, and tetrandrine, have anti-new coronavirus effects, but their antiviral activity is not strong and their cytotoxicity is high, so their selectivity index / therapeutic index (SI) is low, and there are potential safety concerns.

[0006] As described above, there is a strong need in the field to develop novel, safer cyclic bisbenzyltetrahydroisoquinoline compounds for the inhibition of SARS-CoV-2 coronavirus and the treatment of pneumonia caused by novel coronavirus infection.

[0007] In addition, the inventors further explored other potential uses of the cyclic bisbenzyltetrahydroisoquinoline compounds and found that CD4 + It was found that it has the effect of suppressing in vitro differentiation of CD4 T cells. + Autoimmunity mediated by T cells (Th1 and Th17 cells) has already been implicated as a contributing factor in multiple sclerosis. Th1 CD4 + T cells and Th17 CD4 secreting interleukin-17 (IL-17A) +T cells play an important role in mouse experimental autoimmune encephalomyelitis (EAE) models, and T cell polarization, leukocyte migration, and infiltration into the central nervous system are crucial processes in the pathogenesis of EAE. For example, mice with low numbers of Th17 cells are less susceptible to EAE, and Th17 cells have been isolated from lesions in brain tissues of MS patients. Increasing evidence indicates that Th17 (characterized by the production of IL-17) is not less important than Th1 in the pathogenesis of multiple sclerosis (MS). However, there is still no specific drug for the treatment of MS, and most of the regulatory factors disclosed are transcription factors or cytokines. Small molecules that can regulate the differentiation of Th1 and Th17 cells, especially those that simultaneously suppress the differentiation of Th1 and Th17 cells, have not yet been reported, and such molecules have the potential for future use in anti-MS.

[0008] Th17 cells are involved in maintaining immune stability, especially at the intestinal mucosal surface, and lead to chronic inflammation associated with autoimmune diseases such as rheumatoid arthritis. Th17 cells play an important role in the pathogenesis of rheumatoid arthritis by mediating immune dysfunction, especially early in the progression of the disease. Inhibition of hyperdifferentiation of Th17 cells can alleviate or prevent the development and progression of rheumatoid arthritis.

[0009] Th17 cells play an important role in the process of host defense against foreign pathogens, and besides their role in infectious diseases, Th17 cells are also involved in the pathogenesis of liver diseases, such as viral hepatitis, autoimmune liver disease and metabolic liver disease. Pathogenic Th17 cells also play an important role in liver diseases that occur in response to toxicity or metabolic damage, such as hepatitis B virus (HBV) / hepatitis C virus (HCV) infection, nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), hepatocellular carcinoma (HCC) and cholestatic liver disease. Patients with various acute and chronic liver injuries have increased numbers of Th17 cells in the liver and serum. Th17 cells secrete two types of cytokines, IL-17 and IL-22, which are important in the progression of inflammation. IL-17 receptors are expressed in various cells, including monocytes, cholangiocytes and Ito cells, and activation of the receptor induces the secretion of inflammatory cytokines, such as IL-1β, IL-6, TNF and TGFβ. IL-17 also directly induces the production of fibrillar collagen I in Ito cells via the signal transduction and activator of transcription 3 (STAT3) signal pathway. In addition, IL-22 has a pro-inflammatory effect in hepatitis B virus infection. Therefore, compounds that have the effect of suppressing the hyperdifferentiation of Th17 may have the effect of alleviating liver fibrosis, hepatitis B virus (HBV) / hepatitis C virus (HCV) infection-induced liver disease, nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), hepatocellular carcinoma (HCC) and cholestatic liver disease.

[0010] IL-17A, a glycoprotein secreted by Th17 cells, is also a proinflammatory cytokine involved in chronic inflammation and autoimmune diseases. IL-17A is involved in the development and progression of pulmonary fibrosis in a TGF-β1-dependent and -independent manner, and the IL-17A signaling pathway is a potential therapeutic target for treating fibroproliferative lung diseases. Inhibiting IL-17A secretion can also ameliorate silica-induced lung dysfunction, pulmonary inflammation and fibrosis in mice. Thus, inhibiting the hyperdifferentiation of Th17 cells capable of secreting IL-17A can reduce IL-17A levels and alleviate the progression of many pulmonary fibrotic diseases, including silicosis.

[0011] There are few reports of small molecules with good drug-like properties that can simultaneously suppress Th1 and Th17 cell differentiation. Such molecules have potential applications in the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, systemic lupus erythematosus, systemic sclerosis, neuromyelitis optica, autoimmune enteritis, autoimmune hepatitis, and diseases including liver fibrosis, pulmonary fibrosis, renal fibrosis, scleroderma, and silicosis. They are also expected to alleviate liver lesions including liver fibrosis, hepatitis B virus (HBV) / hepatitis C virus (HCV)-infected liver disease, nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), hepatocellular carcinoma (HCC), and cholestatic liver disease. Summary of the Invention [Problem to be solved by the invention]

[0012] The object of the present invention is to provide a safer inhibitor that suppresses the activity of viruses, particularly the SARS-CoV-2 coronavirus, as well as a method for producing the same and its use in the treatment, prevention and alleviation of diseases such as pneumonia caused by viral infections, particularly novel coronavirus infections.

[0013] Another object of the present invention is to provide compounds having anti-inflammatory activity, as well as methods for their preparation and use in the treatment, prevention and alleviation of diseases associated with inflammation, such as pneumonia, non-alcoholic steatohepatitis, colitis, nephritis, pancreatitis, myocarditis, arthritis, inflammatory pain, etc.

[0014] Another object of the present invention is to provide compounds having antifibrotic activity, as well as methods for their preparation and use in the treatment, prevention and alleviation of diseases associated with fibrosis, such as pulmonary fibrosis, silicosis, liver fibrosis, kidney fibrosis, myocardial fibrosis, skin fibrosis, retinal fibrosis, bone marrow fibrosis, and inflammatory pain.

[0015] Another object of the present invention is to provide an inhibitor that suppresses T cell differentiation, particularly Th1 and Th17 cell differentiation, as well as a method for preparing the same and its use in the treatment, prevention and alleviation of autoimmune diseases associated with abnormalities in T cell differentiation, such as psoriasis, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, neuromyelitis optica, myasthenia gravis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, delayed type hypersensitivity reaction, graft-versus-host disease, etc. [Means for solving the problem]

[0016] In a first aspect of the present invention, there is provided a cyclic bisbenzyltetrahydroisoquinoline compound represented by formula I, or a pharma- ceutically acceptable salt thereof, or an enantiomer, diastereomer, racemate, or a crystalline hydrate or solvate thereof, or a mixture thereof. [ka] (In the formula, R1 and R2 each independently represent a hydrogen atom, a halogen atom, a nitro group, a hydroxy group, a mercapto group, a C1-C6 alkoxy group, a C1-C6 haloalkoxy group, a hydroxy C1-C6 alkoxy group, a C1-C6 alkylthio group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, an amino C1-C6 alkyl group, a hydroxy C1-C6 alkyl group, a cyano C1-C6 alkyl group, a C3-C8 cycloalkyl group, a C3-C8 cycloalkyloxy group, or a C2-C6 alkenyl group. , C2-C6 alkenylcarbonyl group, C2-C6 alkenyloxy group, C2-C6 alkynyl group, C2-C6 alkynyloxy group, amino group, amino group substituted with C1-C6 alkyl group, amino group substituted with benzyl group, amino group substituted with C1-C6 alkanoyl group, amino group substituted with C2-C6 alkenylcarbonyl group, cyano group, C1-C6 carboxy group, C1-C6 aldehyde group, C1-C6 alkanoyl group, C3-C6 cycloalkylcarbonyl group, a C1-C6 haloalkanoyl group, a sulfonylamino group, a sulfonylamino group substituted with a C1-C6 alkyl group, a carbamoyl group, a phenylcarbamoyl group, an N-methyl-N-methoxyamino group, a carbamoyl group substituted with a C1-C6 alkyl group, a carbamoyl group substituted with a C3-C6 cycloalkyl group, an adamantylcarbamoyl group, a carbamoyl group substituted with a pyridyl group or a pyrimiridyl group, a hydroxy C1-C6 alkoxy C1-C6 alkyl group, Substituted carbamoyl group, carbamoyl group substituted with C1-C6 alkoxy C1-C6 alkyl group, C1-C6 alkoxycarbonyl group substituted with hydroxy C1-C6 alkoxy group, phenoxycarbonyl group, hydroxymethyl group substituted with C3-C6 cycloalkyl group, carboxy C1-C6 alkyl group, C1-C6 alkylsulfonyl group, C1-C6 haloalkylsulfonyl group, amino C1-C6 alkyl group substituted with C1-C6 alkyl group, C1-C6 alkyl group, C1-C6 alkylsulfonyl ... 20 Carbamoyloxy group substituted with alkyl group (or carbamoyloxy group substituted with C1-C6 alkyl group), C3-C 10Carbamoyloxy group substituted with cycloalkyl group, amino C1-C6 alkyl group substituted with C1-C6 alkanoyl group, C1-C6 alkoxycarbonyl group, carbamoyl C1-C6 alkyl group, carbamoyl C1-C6 alkyl group substituted with C1-C6 alkyl group, C2-C6 alkenylcarbonyloxy group (C2-C6 alkenyl-CO-O-), C2-C 10 Ester groups, [ka] or -OZ, where Z is [ka] It is. where n is 0, 1, 2, 3, or 4. m is 1, 2, 3, or 4. Here, the phenylcarbamoyl group and the phenoxycarbonyl group may be substituted with one or more substituents selected from F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 alkoxy group, and a C1-C6 haloalkoxy group, if necessary. Alternatively, R1 and R2 together with the adjacent benzene ring form a benzo[5-6 membered monocyclic heterocycle] which is substituted or unsubstituted with 1 to 4 substituents, the substituents being selected from halogen, hydroxyl group, mercapto group, oxo, thio, C1 to C6 alkyl group, C1 to C6 alkoxy group, and cyano group, and the heterocycle contains 1 to 3 heteroatoms selected from N, O, and S. An additional proviso is that the compound does not include the following compounds: [ka]

[0017] In another preferred embodiment, the compound does not include the following compounds: [ka] In another preferred embodiment, the compound of formula I is a non-natural product.

[0018] In another preferred embodiment, the benzo[5-6 membered monocyclic heterocycle] is [ka] Selected from.

[0019] In another preferred embodiment, R1 and R2 are each independently selected from hydrogen, halogen, a nitro group, a hydroxy group, a mercapto group, a C1-C4 alkoxy group, a C1-C4 haloalkoxy group, a hydroxy C1-C4 alkoxy group, a C1-C4 alkylthio group, a C1-C4 alkyl group, a C1-C4 haloalkyl group, an amino C1-C4 alkyl group, a hydroxy C1-C4 alkyl group, a cyano C1-C4 alkyl group, a C3-C6 cycloalkyl group, a C3-C6 cycloalkyloxy group, a C2-C5 aryl group, a C3-C6 aryloxy group, a C2-C5 aryloxy ... C2-C5 alkenyl group, C2-C5 alkenylcarbonyl group, C2-C5 alkenyloxy group, C2-C5 alkynyl group, C2-C5 alkynyloxy group, amino group, amino group substituted with C1-C4 alkyl group, amino group substituted with benzyl group, amino group substituted with C1-C4 alkanoyl group, amino group substituted with C2-C5 alkenylcarbonyl group, cyano group, C1-C4 carboxy group, C1-C4 aldehyde group, C1-C4 alkanoyl group, C3-C5 cycloalkylcarbonyl group, C1-C4 4Haloalkanoyl group, sulfonylamino group (-SO2NH2), sulfonylamino group substituted with C1-C4 alkyl group (-SO2NH2), carbamoyl group (-CONH2), phenylcarbamoyl group, N-methyl-N-methoxyamino group, carbamoyl group substituted with C1-C4 alkyl group, carbamoyl group substituted with C3-C5 cycloalkyl group, adamantylcarbamoyl group, carbamoyl group substituted with pyridyl group or pyrimiridyl group, hydroxy C1-C4 alkoxy C Carbamoyl group substituted with 1-C4 alkyl group, carbamoyl group substituted with C1-C4 alkoxy C1-C4 alkyl group, C1-C4 alkoxycarbonyl group substituted with hydroxy C1-C4 alkoxy group, phenoxycarbonyl group, hydroxymethyl group substituted with C3-C5 cycloalkyl group, carboxy C1-C4 alkyl group, C1-C4 alkylsulfonyl group, C1-C4 haloalkylsulfonyl group, amino C1-C4 alkyl group substituted with C1-C4 alkyl group, C1-C 10a carbamoyloxy group substituted with an alkyl group (or a carbamoyloxy group substituted with a C1-C4 alkyl group), a carbamoyloxy group substituted with a C3-C8 cycloalkyl group, an amino C1-C4 alkyl group substituted with a C1-C4 alkanoyl group, a C1-C4 alkoxycarbonyl group, a carbamoyl C1-C4 alkyl group, a carbamoyl C1-C4 alkyl group substituted with a C1-C4 alkyl group, a C2-C5 alkenylcarbonyloxy group (C2-C5 alkenyl-CO-O-), a C2-C6 ester group, [ka] or -OZ, where Z is [ka] where n is 0, 1, 2, 3, or 4, and m is 1, 2, 3, or 4. Alternatively, R1 and R2 together with the adjacent benzene ring may form a benzo[5-6 membered monocyclic heterocycle] substituted or unsubstituted with 1-2 substituents, wherein the substituents are selected from halogen, hydroxyl, mercapto, oxo (=O), thio (=S), C1-C6 alkyl, C1-C6 alkoxy, and cyano, and wherein the heterocycle contains 1-3 heteroatoms selected from N, O, and S.

[0020] In another preferred embodiment, in the compound, R1 and R2 are each independently hydrogen, fluorine, chlorine, bromine, a nitro group, a hydroxy group, a mercapto group, a methoxy group, an ethoxy group, a trifluoromethoxy group, -SCH3, -SCH2CH3, a propyl group, a cyclopropyl group, an isopropyl group, a t-butyl group, a trifluoromethyl group, a difluoromethoxy group, a bromomethyl group, a chloromethyl group, a vinyl group, a vinylmethyl group, an amino group, an N-methylamino group, an N-ethylamino group, an N,N-dimethylamino group, an N,N-diethylamino group, a cyano group, a carboxy group, an aldehyde group, -CH2NH2, -CH2CH2NH2, -CH2OH, -CH2CH2OH, -CH2CN, -CH2CH2CN, a formyl group, an acetyl group, a propionyl group, group, a trifluoroacetyl group, a sulfonylamino group, a carbamoyl group, an N-methylcarbamoyl group, an N,N-dimethylcarbamoyl group, an N-ethylcarbamoyl group, an N,N-diethylcarbamoyl group, -O(C=O)NH(C4 alkyl), a cyclopentylcarbamoyloxy group, a cyclohexylcarbamoyloxy group, -CH2CO2H, -CH2CH2CO2H, -SO2CH3, -SO2CF3, -CH2NHMe, -CH2NMe2, -CH2CONH2, -CONH2, -NHCOCH3, -CH2NHCOCH3, -(C=O)OCH2CH2OCH2CH2OH, -(C=O)OCH3, -CH2CONHMe, -CONHMe, -CONH(cyclopropyl), -CH2CONMe2, or -OZ, where Z is [ka] where n is an integer between 0 and 4. Alternatively, R1 and R2 together with the adjacent benzene ring may form an unsubstituted or substituted benzo[5-6 membered monocyclic heterocycle], the substituents being selected from halogen, hydroxyl, mercapto, oxo, thio, and C1-C6 alkyl groups, and the heterocycle containing 1-3 heteroatoms selected from N, O, and S.

[0021] In another preferred embodiment, R1 is hydrogen, fluorine, chlorine, bromine, a mercapto group, a methoxy group, an ethoxy group, a trifluoromethoxy group, -SCH3, -SCH2CH3, a propyl group, a cyclopropyl group, an isopropyl group, a t-butyl group, a trifluoromethyl group, a difluoromethoxy group, a vinyl group, a vinylmethyl group, an amino group, an N-methylamino group, an N-ethylamino group, an N,N-dimethylamino group, an N,N-diethylamino group, a cyano group, a carboxy group, an aldehyde group, -CH2NH2, -CH2CH2NH2, -CH2 OH, -CH2CH2OH, -CH2CN, -CH2CH2CN, formyl group, acetyl group, propionyl group, trifluoroacetyl group, sulfonylamino group, carbamoyl group, N-methylcarbamoyl group, N,N-dimethylcarbamoyl group, N-ethylcarbamoyl group, N,N-diethylcarbamoyl group, -CH2CO2H, -CH2CH2CO2H, -CH2NHMe, -CH2NMe2, -CH2CONH2, -NHCOCH3, -CH2NHCOCH3, -CH2CONHMe or -CH2CONMe2.

[0022] In another preferred embodiment, R1 is a carbamoyl group, an N-methylcarbamoyl group, an N,N-dimethylcarbamoyl group, an N-ethylcarbamoyl group, an Nn-propylcarbamoyl group, an N-isopropylcarbamoyl group, an N-cyclopropylcarbamoyl group, an N,N-diethylcarbamoyl group, or an N-cyclopropylcarbamoyl group.

[0023] In another preferred embodiment, R2 is hydrogen, fluorine, chlorine, bromine, a nitro group, an amino group, an N-methylamino group, an N-ethylamino group, an N,N-dimethylamino group, an N,N-diethylamino group, a sulfonylamino group, or -NHCOCH3. In another preferred embodiment, the compound of formula I is chiral or non-chiral.

[0024] In another preferred embodiment, the compound has a structure represented by formula Ia: [ka]

[0025] In another preferred embodiment, the compound has the structure of formula Ib: [ka]

[0026] In another preferred embodiment, the compound of formula (I) is selected from the following compounds: [ka] [ka] [ka] [ka] [ka]

[0027] In another preferred embodiment, the compound of formula (I) is selected from the following compounds: [ka]

[0028] In a second aspect of the present invention, there is provided a method for producing a cyclic bisbenzylisoquinoline compound according to the first aspect of the present invention, the method comprising the steps of: a) using a cyclic bisbenzylisoquinoline containing a phenolic hydroxy group as a raw material, the cyclic bisbenzylisoquinoline compound is obtained by alkylating the raw material with an alkylating agent; b) using a cyclic bisbenzylisoquinoline containing a phenolic hydroxy group as a raw material, an acylation reaction with an acylating agent to obtain the cyclic bisbenzylisoquinoline compound; c) reacting oxyacanthin with a sulfonylating agent in the presence of a base to obtain compound (I-1b); (I-1b) is subjected to a coupling reaction with a coupling reagent to obtain a cyclic bisbenzylisoquinoline compound I-1 represented by formula I-1, and the reaction is shown in Reaction Scheme 1; [ka] (In formula I-1, R1 is selected from hydrogen, halogen, a C1-C6 alkylthio group, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, an amino group substituted with a C1-C6 alkyl group, an amino group substituted with a benzyl group, a cyano group, a carboxy group, an aldehyde group, and a C1-C6 alkanoyl group. In formula 1-1b, L is selected from leaving groups. d) As shown in the following reaction scheme 2, oxyacanthin is used as a raw material to produce the compound of formula (I-2) through nitration, reduction and ring-closing reactions; [ka] (In formula I-2, R1 and R2 together with the adjacent benzene ring form a benzo[5-6 membered monocyclic heterocycle] which is unsubstituted or substituted with 1-4 substituents.) e) As shown in reaction scheme 3, oxyacanthin is used as a raw material to produce the compound of formula (I-3) through a multi-step reaction; [ka] (In formula I-3, R1 and R2 together with the adjacent benzene ring form a benzo[5-6 membered monocyclic heterocycle] which is unsubstituted or substituted with 1-4 substituents.) f) The compounds obtained by methods a) to e) are subjected to functional group conversion to obtain the cyclic bisbenzyltetrahydroisoquinoline compound.

[0029] In the above method, the raw material "oxyacanthin" is present in the form of oxyacanthin, a pharma- ceutically acceptable salt thereof, or an enantiomer, diastereomer, racemate, or a crystalline hydrate or solvate thereof, or a mixture thereof. In another preferred embodiment, the method uses oxyacanthin as a raw material, and subjecting it to a condensation acylation reaction with a carboxylic acid to obtain the cyclic bisbenzyltetrahydroisoquinoline compound.

[0030] In another preferred embodiment, the condensation acylation reaction is carried out in the presence of a condensing agent, and the condensing agent is selected from the group consisting of N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), or a combination thereof.

[0031] In another preferred embodiment, the leaving group L is selected from a C1-C6 alkylsulfonyloxy group, a C1-C6 haloalkylsulfonyloxy group, a benzenesulfonyloxy group, a naphthalenesulfonyloxy group, or a combination thereof, and preferably, L is a methanesulfonyloxy group or a trifluoromethanesulfonyloxy group.

[0032] In another preferred embodiment, the sulfonylation reagent is selected from C1-C6 alkylsulfonyl chloride, C1-C6 alkylsulfonic anhydride, benzenesulfonyl chloride, benzenesulfonic anhydride, naphthalenesulfonyl chloride, naphthalenesulfonic anhydride, preferably methanesulfonyl chloride, methanesulfonic anhydride, trifluoromethanesulfonyl chloride and trifluoromethanesulfonic anhydride.

[0033] In another preferred embodiment, the solvent is selected from dichloromethane, tetrahydrofuran, N,N-dimethylformamide, methanol, ethanol, acetonitrile, toluene, acetone, dioxane, and chloroform. In another preferred embodiment, the base is selected from an inorganic base or an organic base.

[0034] In another preferred embodiment, the inorganic base is selected from sodium hydroxide, potassium hydroxide, cesium hydroxide, barium hydroxide, potassium hydride, sodium hydride, sodium t-butoxide, potassium t-butoxide, potassium carbonate, sodium carbonate, or calcium carbonate, and the organic base is selected from pyridine, triethylamine, diisopropylethylamine, N,N-dimethylaniline, and N,N-dimethylpyridine.

[0035] In another preferred embodiment, the coupling reaction is carried out in the presence of a palladium catalyst and a base. In another preferred embodiment, the palladium catalyst is palladium acetate (Pd(OAc)2), bis(triphenylphosphine)palladium dichloride ((Ph3P)2PdCl2), bis(benzonitrile)palladium dichloride ((PhCN)2PdCl2), tetrakis(triphenylphosphine)palladium (Pd(PPh3)4), bis(triphenylphosphine)palladium acetate ((Ph3P)2Pd(Oac)2), 1,2-bis(diphenylphosphino)ethanepalladium dichloride ((PdCl2(d ppe)2), bis[1,2-bis(diphenylphosphino)ethane]palladium (Pd(dppe)2), bis(dibenzylideneacetone)palladium (Pd(dba)2), tris(dibenzylideneacetone)dipalladium (Pd2(dba)3), [1,3-bis(diphenylphosphino)propane]palladium dichloride (PdCl2(dippp)), and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (Pd(dppf)Cl2), or combinations thereof.

[0036] In another preferred embodiment, Reaction Scheme 1 may further include a reaction solvent that does not interfere with other reactions. In another preferred embodiment, Reaction Scheme 1 may further include a suitable ligand as a reaction promoter.

[0037] In another preferred embodiment, the suitable ligand is selected from 2,2'-diphenylphosphino-1,1'-binaphthyl (BINAP), tri-t-butyl group (P(t-Bu)3), 1,1'-bis(diphenylphosphino)ferrocene (dppf), 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl (x-phos), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos), tri-t-butylphosphonium tetrafluoroborate and tris(2-methylphenyl)phosphine (P(o-tolyl)3), or a combination thereof.

[0038] In another preferred embodiment, the coupling reagent is selected from C1-C6 alkylboronic acid, cyclopropylboronic acid, benzylamine, potassium cyanide, zinc cyanide, tributyl(vinyl)tin, CO, CO2, formic acid, sodium formate, lithium formate, C1-C6 alkylthiol sodium, sodium methanesulfonate, or a combination thereof.

[0039] In another preferred embodiment, the benzo[5-6 membered monocyclic heterocycle] is [ka] Selected from. In another preferred embodiment, in benzo[5-6 membered monocyclic heterocycle], the substituents are selected from halogen, hydroxyl, mercapto, amino, oxo (=O), thio (=S), and C1-C6 alkyl groups, and the heterocycle contains 1-3 heteroatoms selected from N, O, and S.

[0040] In another preferred embodiment, in the nitration reaction, the nitrating reagent is selected from nitric acid, a mixture of concentrated sulfuric acid and nitric acid, a mixture of nitric acid, sodium nitrate and concentrated sulfuric acid, a mixture of potassium nitrate and concentrated sulfuric acid, a mixture of sodium nitrite and concentrated sulfuric acid, and a mixture of acetic acid and nitric acid. In another preferred embodiment, in the nitration reaction, the nitrating reagent is a mixture of acetic acid and nitric acid. In another preferred embodiment, the mixing ratio of the mixture is not limited. In another preferred embodiment, the temperature of the nitration reaction is from −20° C. to room temperature.

[0041] In another preferred embodiment, the reduction reaction is catalyzed by Pd / C. In another preferred embodiment, the reduction reaction uses hydrogen gas, ammonium formate or formic acid as a reducing agent. In another preferred embodiment, the reduction reaction is carried out in a lower alcohol or a lower alcohol-water mixed solvent.

[0042] In another preferred embodiment, the lower alcohol is selected from methanol, ethanol, isopropanol, or a combination thereof. In another preferred embodiment, the reduction reaction is carried out at a temperature within the range of 0 to 100°C, preferably 0 to 40°C.

[0043] In another preferred embodiment, the reduction reaction is carried out at normal pressure. In another preferred embodiment, the reduction reaction is hydrogenated for 1 to 10 hours. In another preferred embodiment, the ring-closing reaction is carried out in the presence of a ring-closing reagent.

[0044] In another preferred embodiment, the ring-closing reagent comprises phosgene, triphosgene, 1,1′-carbonyldiimidazole (CDI), urea, carbon tetrabromide, formic acid, trimethyl orthoformate, trimethyl orthoacetate, triethyl orthoacetate, acetyl chloride, chloroacetyl chloride, bromoacetyl bromide, bromoacetyl chloride, or a combination thereof. In another preferred embodiment, the ring-closing reaction is carried out in the presence or absence of a base. In another preferred embodiment, the base is selected from inorganic bases or organic bases, wherein the inorganic base is selected from sodium hydroxide, potassium hydroxide, potassium hydride, sodium hydride, sodium t-butoxide, potassium t-butoxide, potassium carbonate, sodium carbonate, cesium carbonate and sodium bicarbonate, and the organic base is selected from pyridine, triethylamine, diisopropylethylamine, N,N-dimethylaniline and N,N-dimethylpyridine.

[0045] In another preferred embodiment, Reaction Scheme 2 may further include a reaction solvent that does not interfere with other reactions. In another preferred embodiment, in benzo[5-6 membered monocyclic heterocycle], the substituents are selected from halogen, hydroxyl, mercapto, amino, oxo (=O), thio (=S), and C1-C6 alkyl groups, and the heterocycle contains 1-3 heteroatoms selected from N, O, and S.

[0046] In another preferred embodiment, the benzo[5-6 membered monocyclic heterocycle] is [ka] Selected from. In formula I-3b, L is a leaving group.

[0047] In another preferred embodiment, the leaving group L is selected from the group consisting of a C1-C6 alkylsulfonyloxy group, a C1-C6 haloalkylsulfonyloxy group, a benzenesulfonyloxy group, a naphthalenesulfonyloxy group, preferably a methanesulfonyloxy group and a trifluoromethanesulfonyloxy group.

[0048] In another preferred embodiment, the method e) comprises the steps of: e1) subjecting a compound of formula (I-1a) to an ortho-nitration reaction with a nitrating agent to produce a compound of formula (I-3a); e2) reacting the compound of formula (I-3a) with a sulfonylating agent in the presence of a base in a suitable solvent to obtain a compound of formula (I-3b); e3) compound of formula (I-3b) is reacted with benzylamine in a Buchwald-Hartwig reaction to obtain compound of formula (I-3c); e4) subjecting the compound of formula (I-3c) to a reduction reaction to obtain a compound of formula (I-3d); e5) Compound (I-3) is obtained by subjecting compound (I-3d) to a ring-closing reaction.

[0049] In another preferred embodiment, the nitrating reagent in step e1) is a mixture of concentrated sulfuric acid and nitric acid, a mixture of nitric acid, sodium nitrate and concentrated sulfuric acid, a mixture of potassium nitrate and concentrated sulfuric acid, a mixture of sodium nitrite and concentrated sulfuric acid, a mixture of acetic acid and nitric acid, preferably a mixture of acetic acid and nitric acid. In another preferred embodiment, the mixing ratio of the mixture is not limited.

[0050] In another preferred embodiment, the temperature of the nitration reaction is from −20° C. to room temperature. In another preferred embodiment, the nitration reaction time is 10 minutes to 12 hours.

[0051] In another preferred embodiment, the sulfonylation reagent in step e2) is selected from C1-C6 alkylsulfonyl chloride, C1-C6 alkylsulfonic anhydride, benzenesulfonyl chloride, benzenesulfonic anhydride, naphthalenesulfonyl chloride, naphthalenesulfonic anhydride, preferably methanesulfonyl chloride, methanesulfonic anhydride, trifluoromethanesulfonyl chloride and trifluoromethanesulfonic anhydride.

[0052] In another preferred embodiment, the solvent in step e2) is selected from dichloromethane, tetrahydrofuran, N,N-dimethylformamide, methanol, ethanol, acetonitrile, toluene, acetone, dioxane and chloroform.

[0053] In another preferred embodiment, the base in step e2) is selected from an inorganic base or an organic base, wherein the inorganic base is selected from sodium hydroxide, potassium hydroxide, cesium hydroxide, barium hydroxide, potassium hydride, sodium hydride, sodium t-butoxide, potassium t-butoxide, potassium carbonate, sodium carbonate or calcium carbonate, and the organic base is selected from pyridine, triethylamine, diisopropylethylamine, N,N-dimethylaniline and N,N-dimethylpyridine. In another preferred embodiment, the coupling reaction in step e3) is carried out in the presence of a palladium catalyst and a base.

[0054] In another preferred embodiment, the palladium catalyst is palladium acetate (Pd(OAc)2), bis(triphenylphosphine)palladium dichloride ((Ph3P)2PdCl2), bis(benzonitrile)palladium dichloride ((PhCN)2PdCl2), tetrakis(triphenylphosphine)palladium (Pd(PPh3)4), bis(triphenylphosphine)palladium acetate ((Ph3P)2Pd(OAc)2), 1,2-bis(diphenylphosphino)ethanepalladium dichloride ((PdCl2(d ppe)2), bis[1,2-bis(diphenylphosphino)ethane]palladium (Pd(dppe)2), bis(dibenzylideneacetone)palladium (Pd(dba)2), tris(dibenzylideneacetone)dipalladium (Pd2(dba)3), [1,3-bis(diphenylphosphino)propane]palladium dichloride (PdCl2(dippp)), and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (Pd(dppf)Cl2), or combinations thereof.

[0055] In another preferred embodiment, the base is selected from bis(trimethylsilyl)amino sodium, potassium t-butoxide, sodium t-butoxide, cesium carbonate, potassium phosphate, sodium phosphate, sodium methoxide, sodium ethoxide, potassium hydroxide, sodium hydroxide, potassium fluoride, sodium fluoride, tetrabutylammonium fluoride (TBAF), sodium acetate, potassium acetate, cesium carbonate, potassium carbonate, and sodium carbonate, or a combination thereof.

[0056] In another preferred embodiment, the reaction may further include other reaction solvents that do not interfere with the reaction. In another preferred embodiment, the reaction of step e3) may be carried out by further adding a suitable ligand as a reaction promoter.

[0057] In another preferred embodiment, the suitable ligand is selected from the group consisting of 2,2'-diphenylphosphino-1,1'-binaphthyl (BINAP), tri-t-butyl group (P(t-Bu)3), 1,1'-bis(diphenylphosphino)ferrocene (dppf), 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl (x-phos), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos), tri-t-butylphosphonium tetrafluoroborate or tris(2-methylphenyl)phosphine (P(o-tolyl)3).

[0058] In another preferred embodiment, the reduction reaction in step e4) is catalyzed by Pd / C, palladium hydroxide or palladium hydroxide on carbon. In another preferred embodiment, the reduction reaction in step e4) uses ammonium formate or hydrogen gas as a reducing agent.

[0059] In another preferred embodiment, the reduction reaction is carried out in a lower alcohol or a lower alcohol-water mixed solvent. In another preferred embodiment, the lower alcohol is selected from methanol, ethanol, isopropanol, or a combination thereof.

[0060] In another preferred embodiment, the reduction reaction is carried out at a temperature within the range of 20 to 100°C. In another preferred embodiment, the reduction reaction is carried out at normal pressure. In another preferred embodiment, the ring-closing reaction of step e5) is carried out in the presence of a ring-closing reagent.

[0061] In another preferred embodiment, the ring-closing reagent is selected from the group consisting of phosgene, triphosgene, 1,1'-carbonyldiimidazole (CDI), urea, formic acid, sodium nitrite, carbon disulfide, thiophosgene, triethyl orthoacetate, chloroacetic acid, bromoacetic acid, ethyl bromoacetate, methyl bromoacetate, chloroacetamide, or a combination thereof. In another preferred embodiment, the ring-closing reaction is carried out in the presence or absence of a base. In another preferred embodiment, the base is selected from an inorganic base or an organic base.

[0062] In another preferred embodiment, the inorganic base is selected from sodium hydroxide, potassium hydroxide, potassium hydride, sodium hydride, sodium t-butoxide, potassium t-butoxide, potassium carbonate, sodium carbonate, cesium carbonate or sodium bicarbonate, and the organic base is selected from pyridine, triethylamine, diisopropylethylamine, N,N-dimethylaniline and N,N-dimethylpyridine. In another preferred embodiment, step e5) may further include a reaction solvent that does not interfere with other reactions.

[0063] In another preferred embodiment, the leaving group L is selected from the group consisting of a C1-C6 alkylsulfonyloxy group, a C1-C6 haloalkylsulfonyloxy group, a benzenesulfonyloxy group, a naphthalenesulfonyloxy group, preferably a methanesulfonyloxy group and a trifluoromethanesulfonyloxy group.

[0064] In another preferred embodiment, the sulfonylating reagent is selected from C1-C6 alkylsulfonyl chloride, C1-C6 alkylsulfonic anhydride, benzenesulfonyl chloride, benzenesulfonic anhydride, naphthalenesulfonyl chloride, naphthalenesulfonic anhydride, preferably methanesulfonyl chloride, methanesulfonic anhydride, trifluoromethanesulfonyl chloride and trifluoromethanesulfonic anhydride. The solvent is selected from dichloromethane, tetrahydrofuran, N,N-dimethylformamide, methanol, ethanol, acetonitrile, toluene, acetone, dioxane and chloroform.

[0065] In another preferred embodiment, the base is selected from an inorganic base or an organic base. In another preferred embodiment, the inorganic base is selected from sodium hydroxide, potassium hydroxide, cesium hydroxide, barium hydroxide, potassium hydride, sodium hydride, sodium t-butoxide, potassium t-butoxide, potassium carbonate, sodium carbonate and calcium carbonate, and the organic base is selected from pyridine, triethylamine, diisopropylethylamine, N,N-dimethylaniline and N,N-dimethylpyridine.

[0066] In another preferred embodiment, the coupling reaction is carried out in the presence of a palladium catalyst and a base. In another preferred embodiment, the palladium catalyst is palladium acetate (Pd(OAc)2), bis(triphenylphosphine)palladium dichloride ((Ph3P)2PdCl2), bis(benzonitrile)palladium dichloride ((PhCN)2PdCl2), tetrakis(triphenylphosphine)palladium (Pd(PPh3)4), bis(triphenylphosphine)palladium acetate ((Ph3P)2Pd(OAc)2), 1,2-bis(diphenylphosphino)ethanepalladium dichloride ((PdCl2(dpp e)2), bis[1,2-bis(diphenylphosphino)ethane]palladium (Pd(dppe)2), bis(dibenzylideneacetone)palladium (Pd(dba)2), tris(dibenzylideneacetone)dipalladium (Pd2(dba)3), [1,3-bis(diphenylphosphino)propane]palladium dichloride (PdCl2(dippp)), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (Pd(dppf)Cl2), or a combination thereof.

[0067] In another preferred embodiment, the base is selected from bis(trimethylsilyl)amino sodium, potassium t-butoxide, sodium t-butoxide, cesium carbonate, potassium phosphate, sodium phosphate, sodium methoxide, sodium ethoxide, potassium hydroxide, sodium hydroxide, potassium fluoride, sodium fluoride, tetrabutylammonium fluoride (TBAF), sodium acetate, potassium acetate, cesium carbonate, potassium carbonate, sodium carbonate, or a combination thereof.

[0068] In another preferred embodiment, Reaction Scheme 4 may further include other reaction solvents that do not interfere with the reaction. In another preferred embodiment, the reaction of Reaction Scheme 4 may further include a suitable ligand as a reaction promoter to carry out the reaction.

[0069] In another preferred embodiment, the suitable ligand is selected from 2,2'-diphenylphosphino-1,1'-binaphthyl (BINAP), tri-t-butyl group (P(t-Bu)3), 1,1'-bis(diphenylphosphino)ferrocene (dppf), 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl (x-phos), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos), tri-t-butylphosphonium tetrafluoroborate and tris(2-methylphenyl)phosphine (P(o-tolyl)3). The coupling reagent includes, but is not limited to, C1-C6 alkylboronic acid, cyclopropylboronic acid, benzylamine, potassium cyanide, zinc cyanide, tributyl(vinyl)tin, CO, CO2, formic acid, sodium formate, lithium formate, C1-C6 alkylthiol sodium, and sodium methanesulfonate.

[0070] In another preferred embodiment, the functional group conversion reaction includes an oxidative hydrolysis reaction, a borohydride-oxidation reaction, a condensed acylation reaction, a reduction reaction, an acylation reaction, an esterification reaction, a Grignard reaction, a chlorination reaction, or a bromination reaction. In another preferred embodiment, the oxidative hydrolysis reaction is carried out in the presence of an oxidizing agent and a base. In another preferred embodiment, the oxidative hydrolysis system comprises hydrogen peroxide / sodium hydroxide, hydrogen peroxide / potassium hydroxide, hydrogen peroxide / potassium carbonate, hydrogen peroxide / sodium carbonate.

[0071] In another preferred embodiment, the borohydride-oxidation reaction involves the first addition of an olefin group with a boron reagent and then oxidatively hydrolyzing the olefin to an alcohol. In another preferred embodiment, the boron reagent comprises borane, 9-BBN. In another preferred embodiment, the condensation acylation reaction is carried out in the presence of a condensing agent.

[0072] In another preferred embodiment, the condensing agent includes N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU). In another preferred embodiment, the reduction reaction is carried out in the presence of a reducing agent. In another preferred embodiment, the reducing agent includes hydrogen gas, ammonium formate, sodium borohydride, potassium borohydride, diisobutylaluminum hydride (DIBAL), and borane.

[0073] In another preferred embodiment, the acylation reaction is carried out in the presence of an acylating reagent. In another preferred embodiment, the acylating reagent includes acetyl chloride, acetic anhydride, propanoyl chloride, propionic anhydride, methanesulfonyl chloride, and the like: In another preferred embodiment, the esterification reaction system includes, but is not limited to, thionyl chloride / methanol, thionyl chloride / ethanol, and the like.

[0074] In another preferred embodiment, the salification reaction is carried out in the presence of a salification reagent. In another preferred embodiment, the chlorination reagent includes, but is not limited to, thionyl chloride, phosphorus pentachloride, and N-chlorosuccinimide (NCS). In another preferred embodiment, the Grignard reaction is carried out in the presence of a Grignard reagent.

[0075] In another preferred embodiment, the Grignard reagent includes, but is not limited to, methylmagnesium bromide, methylmagnesium chloride, methylmagnesium iodide, and the like. In another preferred embodiment, the bromination reaction is carried out in the presence of a bromination reagent. In another preferred embodiment, the bromination reagent includes, but is not limited to, elemental bromine, N-bromosuccinimide (NBS), and the like.

[0076] In a third aspect of the present invention, there is provided a pharmaceutical composition comprising: (A1) a first active ingredient comprising a therapeutically effective amount of a cyclic bisbenzyltetrahydroisoquinoline compound of formula I according to any one of the first aspects, its enantiomers, diastereomers, racemates, and mixtures of one or more of its pharmaceutically acceptable salts, crystalline hydrates, and solvates; and (B) A pharma- ceutically acceptable carrier.

[0077] In another preferred embodiment, the pharmaceutical composition further comprises (A2) a second active ingredient. In another preferred embodiment, the second active ingredient is selected from (Y1) an RNA replication enzyme inhibitor (e.g., Remdesivir or GS-5734, Favipiravir, Molnupiravir), (Y2) a 3CL enzyme inhibitor (e.g., Nirmatrelvir), (Y3) an antibody, and (Y4) any combination of Y1 to Y3.

[0078] In another preferred embodiment, the antibody comprises an anti-coronavirus antibody. In a fourth aspect of the present invention, there is provided use of a cyclic bisbenzyltetrahydroisoquinoline compound according to the first aspect or a pharmaceutical composition according to the third aspect for the manufacture of an inhibitor for suppressing viral replication, inflammation, fibrosis, abnormal T-cell differentiation, and / or for the manufacture of a medicament for preventing and / or treating a disease associated with viral infection, a disease associated with inflammation (pneumonia, non-alcoholic steatohepatitis, colitis, nephritis, pancreatitis, myocarditis, arthritis, inflammatory pain), a disease associated with fibrosis (pulmonary fibrosis, silicosis, liver fibrosis, renal fibrosis, myocardial fibrosis, skin fibrosis, retinal fibrosis, bone marrow fibrosis), an autoimmune disease associated with Th1 and / or Th17 abnormal differentiation (psoriasis, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, neuromyelitis optica, myasthenia gravis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, delayed type hypersensitivity reaction, graft versus host disease, etc.), osteoporosis, or a neurodegenerative disease.

[0079] In another preferred embodiment, the virus is selected from Filoviridae, Flaviviridae, Paramyxoviridae, Arenaviridae, Coronaviridae, or a combination thereof. In another preferred embodiment, the Filoviridae virus is selected from Marburg virus and Ebola virus.

[0080] In another preferred embodiment, the coronavirus is selected from the group consisting of coronaviruses that infect humans, Severe acute respiratory syndrome coronavirus (SARS-CoV), the 2019 novel coronavirus and its variants (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), coronaviruses that lead to the common cold, or combinations thereof.

[0081] In another preferred embodiment, the coronavirus causing the common cold is human coronavirus OC 43 (Human coronavirus O.C. 43 ), Human coronavirus 229 E, Human coronavirus 229E, Human coronavirus NL63, and Human coronavirus HKUl.

[0082] In another preferred embodiment, the coronavirus infection-related disease is selected from the group consisting of common cold, high-risk symptom infection, respiratory infection, pneumonia and its complications caused by human coronavirus, Corona Virus Disease 2019 (COVID-19) caused by SARS-CoV-2, novel coronavirus epidemic caused by SARS-CoV-2, or a combination thereof.

[0083] In another preferred embodiment, the disease associated with the 2019 novel coronavirus infection is selected from the group consisting of respiratory tract infection, pneumonia and its complications, or a combination thereof. In another preferred embodiment, the use is for the manufacture of (a) an inhibitor that suppresses the replication of the 2019 novel coronavirus (SARS-CoV-2), and / or (b) a drug for treating and / or preventing or alleviating associated diseases caused by the 2019 novel coronavirus (SARS-CoV-2) infection.

[0084] In another preferred embodiment, the disease is pneumonia, non-alcoholic steatohepatitis, colitis, nephritis, pancreatitis, myocarditis, arthritis, inflammatory pain, pulmonary fibrosis, silicosis, liver fibrosis, kidney fibrosis, myocardial fibrosis, skin fibrosis, retinal fibrosis, bone marrow fibrosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, neuromyelitis optica, myasthenia gravis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, delayed hypersensitivity reaction, graft-versus-host disease, osteoporosis, neurodegenerative disease, or a combination thereof.

[0085] In another preferred embodiment, the use is for the manufacture of a medicament for treating and / or preventing or alleviating inflammation, fibrosis, and related diseases caused by abnormal T cell differentiation. Of course, it is understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (for example, in the Examples) can be combined with each other to form new or preferred technical solutions, which will not be described here one by one due to space limitations. [Brief description of the drawings]

[0086] [Figure 1] FIG. 1 shows the inhibitory effects of compounds 1, 2, 3, 4, 6, and 58 on Th1 / Th17 differentiation. [Diagram 2] FIG. 2 shows that compounds 1, 2, 3, 4, 6, 58 do not affect cell vitality in an LPS-induced inflammation model. [Diagram 3] FIG. 3 shows that compounds 1, 2, 4, and 58 can significantly suppress inflammatory factors in the LPS-induced inflammation model. [Figure 4] FIG. 4 shows that compounds 1, 2, 3, 4, 6, 58 do not affect cell vitality in a TNF-α induced inflammation model. [Diagram 5] FIG. 5 shows that compounds 1, 2, 3, 4, 6, and 58 can significantly suppress inflammatory factors in the TNF-α-induced inflammation model. [Figure 6] FIG. 6 shows that compound 4 can significantly suppress acute inflammation induced by LPS in mice. [Figure 7] FIG. 7 shows that compound 1 can significantly improve cell viability in the TNF-α-induced A549 lung cell injury model. [Figure 8] FIG. 8 shows that compounds 3 and 58 can significantly suppress the injury factor in the A549 lung cell injury model induced by TNF-α. [Figure 9] FIG. 9 shows that compounds 1, 2, 3, 4, 6, and 58 can significantly alleviate H2O2-induced ALM12 hepatocyte injury. [Figure 10] Figures 10 and 11 show that compounds 1, 2, and 4 can attenuate A549 lung epithelial cell fibrosis induced by TGF-β1. [Figure 11] Figures 10 and 11 show that compounds 1, 2, and 4 can attenuate A549 lung epithelial cell fibrosis induced by TGF-β1. [Figure 12] FIG. 12 shows that compounds 2 and 4 can alleviate acute liver fibrosis induced by CCl4 in mice. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0087] The present inventors have conducted extensive and in-depth research and conducted extensive screening, and have unexpectedly developed an active ingredient that can effectively inhibit the replication of coronaviruses such as the 2019 novel coronavirus (SARS-CoV-2). Experiments have shown that the active ingredient of the present invention (a cyclic bisbenzyltetrahydroisoquinoline compound represented by formula I or a pharma- ceutically acceptable salt thereof, or an enantiomer, diastereomer, racemate, or crystalline hydrate, solvate, or a mixture thereof) can effectively inhibit the replication and vitality of coronaviruses such as the 2019 novel coronavirus (SARS-CoV-2). Based on this, the present invention has been completed.

[0088] Surprisingly, compared with natural compounds such as oxyacanthine, berbamine, and tetrandrine, the cyclic bisbenzyltetrahydroisoquinoline compounds described in formula I have significantly improved anti-coronavirus activity (the improvement in anti-viral activity reaches about 10-fold or more) and / or low cytotoxicity, and therefore have a better therapeutic index (SI), which is useful for the prevention and treatment of coronaviruses such as SARS-CoV-2 virus, and has good prospects for clinical application.

[0089] In addition, the inventors further explored other potential actions of the cyclic bisbenzylisoquinoline compounds and found that they inhibited CD4 +It was found to have the effect of suppressing the differentiation of T cells. Experiments have shown that the active ingredient of the present invention (cyclic bisbenzylisoquinoline compound represented by formula I or a pharma- ceutically acceptable salt thereof, or an enantiomer, diastereomer, racemate, or crystal hydrate, solvate, or a mixture thereof) has an effect of effectively suppressing viral infection-related diseases, inflammation-related diseases (pneumonia, nonalcoholic fatty liver disease, colitis, nephritis, pancreatitis, myocarditis, arthritis, inflammatory pain), fibrosis-related diseases (pulmonary fibrosis, silicosis, liver fibrosis, kidney fibrosis, myocardial fibrosis, skin fibrosis, retinal fibrosis, bone marrow fibrosis), autoimmune diseases associated with Th1 and / or Th17 abnormal differentiation (psoriasis, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, neuromyelitis optica, myasthenia gravis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, delayed hypersensitivity reaction, graft-versus-host disease, etc.), osteoporosis, and neurodegenerative diseases.

[0090] term As used herein, the terms "compound of the present invention", "cyclic bisbenzyltetrahydroisoquinoline compound", "compound of the present invention that inhibits the activity of coronavirus", and "compound of the present invention that inhibits the replication of coronavirus" can be used interchangeably and refer to a cyclic bisbenzyltetrahydroisoquinoline compound having excellent coronavirus replication inhibitory activity, including a compound represented by formula I, or a pharma- ceutically acceptable salt thereof, or an enantiomer, diastereomer, racemate, or a crystalline hydrate, solvate, or a mixture thereof. The compound of the present invention does not include natural compounds (e.g., tetrandrine, fangchinoline, oxyacanthine).

[0091] As used herein, a "formulation of the invention" is a formulation that contains a compound of the invention. As used herein, the term "comprise" or variations thereof, such as "containing" or "including," is intended to include the element or component described above but not to exclude other elements or other components.

[0092] As used herein, the terms "novel coronavirus," "2019-nCov," or "SARS-CoV-2" may be used interchangeably and refer to the 2019 novel coronavirus, the seventh known human coronavirus and the cause of COVID-19, a severe contagious disease threatening human health worldwide.

[0093] As used herein, halogen is typically fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine or bromine, more preferably fluorine or chlorine. The C1-C6 alkyl group is a linear or branched saturated hydrocarbon group containing 1 to 6 carbon atoms, such as a methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, t-butyl group, sec-butyl group, n-pentyl group, 1-ethylpropyl group, isopentyl group, neopentyl group, isohexyl group, 3-methylpentyl group, n-hexyl group, etc., preferably a methyl group, ethyl group, n-propyl group, isopropyl group, butyl group, isobutyl group or t-butyl group.

[0094] The C1-C6 haloalkyl group refers to a linear or branched saturated hydrocarbon group containing 1 to 6 carbon atoms in which one or more hydrogen atoms are substituted with the same or different halogen atoms, such as a trifluoromethyl group, a fluoromethyl group, a difluoromethyl group, a chloromethyl group, a bromomethyl group, a dichlorofluoromethyl group, a chloroethyl group, a bromopropyl group, a 2-chlorobutyl group, or a pentafluoroethyl group.

[0095] The C1-C6 alkoxy group refers to a straight or branched alkoxy group containing 1 to 6 carbon atoms, for example, a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, a t-butoxy group, a sec-butoxy group, an n-pentoxy group, an isopentoxy group, a neopentoxy group, an isohexoxy group, a 3-methylpentoxy group, an n-hexoxy group, or the like, preferably a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, or a t-butoxy group.

[0096] A C1-C6 haloalkoxy group is a straight or branched alkoxy group containing 1-6 carbon atoms in which one or more hydrogen atoms are substituted with the same or different halogen atoms, such as, for example, -OCF3, -OCH2CH2Cl, -OCHBrCH2Cl or -OCF2CF3. The C1-C6 alkylthio group refers to a straight-chain or branched-chain alkylthio group containing 1 to 6 carbon atoms, for example, a methylthio group, an ethylthio group, an n-propylthio group, an isopropylthio group, an n-butylthio group, an isobutylthio group, a t-butylthio group, a sec-butylthio group, an n-pentylthio group, an isopentylthio group, a neopentylthio group, or an n-hexylthio group, preferably a methylthio group, an ethylthio group, an n-propylthio group, an isopropylthio group, an n-butylthio group, an isobutylthio group, or a t-butylthio group.

[0097] The C2-C6 alkenyl group is a straight-chain or branched-chain unsaturated hydrocarbon group containing 1 to 3 double bonds and 2 to 6 carbon atoms, and includes both cis and trans configurations, such as a vinyl group, a 1-propenyl group, a 2-propenyl group, a 1-methyl-1-propenyl group, a 2-methyl-1-propenyl group, a 2-methyl-2-propenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a 1-pentenyl group, a 2-pentenyl group, a 3-pentenyl group, a 4-pentenyl group, a 1,3-butadienyl group, a 1,3-pentadienyl group, a 1-hexenyl group, a 2-hexenyl group, a 3-hexenyl group, a 4-hexenyl group, a 5-hexenyl group, a 3,3-dimethyl-1-propenyl group, or a 2-butenyl-1-propenyl group.

[0098] A C2-C6 alkynyl group is a straight or branched alkynyl group containing 2 to 6 carbon atoms, such as an ethynyl group, a 2-propargyl group, a 2-butynyl group, a 3-butynyl group, a 1-methyl-2-propargyl group, a 2-pentynyl group, a 2-pentynyl group, or a 2-hexynyl group. The C2-C6 alkenyloxy group is a straight-chain or branched-chain alkenyloxy group containing 1 to 3 double bonds and 2 to 6 carbon atoms, such as a vinyloxy group, a 1-propenyloxy group, a 1-methyl-1-propenyloxy group, a 2-methyl-1-propenyloxy group, a 1-pentenyloxy group, a 1,3-pentadienyloxy group, or a 2-pentenyloxy group.

[0099] The C2-C6 alkynyloxy group is a straight-chain or branched-chain alkynyloxy group containing 2 to 6 carbon atoms, such as an ethynyloxy group, a 2-propynyloxy group, a 2-butynyloxy group, a 3-butynyloxy group, a 1-methyl-2-propenyloxy group, a 2-pentynyloxy group, or a 2-hexynyloxy group. The C1-C6 alkanoyl group is a straight or branched alkanoyl group containing 1 to 6 carbon atoms, such as a formyl group, an acetyl group, a propionyl group, a butanoyl group, an isobutanoyl group, a pentanoyl group, a t-butanoyl group, or a hexanoyl group.

[0100] The C1-C6 haloalkanoyl group is a straight or branched alkanoyl group containing 1 to 6 carbon atoms in which one or more hydrogen atoms are substituted with the same or different halogen atoms, such as a trifluoroacetyl group. The carbamoyl group substituted with a C1-C6 alkyl group means a carbamoyl group in which one or two hydrogen atoms are substituted with the same or different C1-C6 alkyl groups, such as -CONHMe, -CONHEt, -CON(Me)Et, -CONEt2 or -CONMe2.

[0101] A carbamoyl group substituted with a hydroxy C1-C6 alkoxy C1-C6 alkyl group means a carbamoyl group in which one or two hydrogen atoms are substituted with the same or different hydroxy C1-C6 alkoxy C1-C6 alkyl groups, such as -CONHCH2OCH2OH, -CONHCH2CH2OCH2CH2OH, etc. A C1-C6 alkoxycarbonyl group substituted with a hydroxy C1-C6 alkoxy group is a C1-C6 alkoxycarbonyl group in which the carbon atom of one alkyl group is linked to the oxygen atom of the hydroxy C1-C6 alkoxy group, and examples include -COOCH2OCH2OH and -COOCH2CH2OCH2CH2OH.

[0102] A hydroxy C1-C6 alkyl group is a straight or branched alkyl group containing 1-6 carbon atoms, one carbon atom of which is linked to a hydroxy group, such as, for example, -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH2CH2CH2OH, -CH2CH2CH2CH2OH or -CH2CH(CH3)CH2OH. An amino C1-C6 alkyl group is a straight or branched alkyl group containing 1-6 carbon atoms, one carbon atom of which is linked to an amino group, such as, for example, -CH2NH2, -CH2CH2NH2, -CH(NH2)CH3, -CH2CH2CH2NH2 or -CH2CH2CH2CH2NH2.

[0103] An amino C1-C6 alkyl group substituted with a C1-C6 alkyl group means an amino group in which one or two hydrogen atoms are substituted with the same or different C1-C6 alkyl groups, such as -CH2NHMe or -CH2CH2NEt2. A carbamoyl C1-C6 alkyl group is a straight or branched alkyl group containing 1-6 carbon atoms in which one carbon atom is linked to the carbonyl carbon of the carbamoyl group, such as -CH2CONH2, -CH2CH2CONH2, -CH(CONH2)CH3 or -CH2CH2CH2CONH2.

[0104] The carbamoyl C1-C6 alkyl group substituted with a C1-C6 alkyl group is a carbamoyl C1-C6 alkyl group in which the hydrogen atom of the amino group is substituted with one or two similar or different C1-C6 alkyl groups, such as -CH2CONHMe, -CH2CH2CONHEt, -CH2CH2CONMe2 or -CH2CONEt2. A cyano C1-C6 alkyl group is a straight or branched alkyl group containing 1 to 6 carbon atoms, one carbon atom of which is linked to a cyano group, and examples of such groups include a cyanomethyl group, a 2-cyanoethyl group, a 1-cyanoethyl group, a 3-cyanopropyl group, a 4-cyanobutyl group, and a 5-cyanopentyl group.

[0105] The carboxy C1-C6 alkyl group is a straight or branched alkyl group containing 1 to 6 carbon atoms, one carbon atom of which is linked to a carboxy group, such as a carboxymethyl group, a 2-carboxyethyl group, a 1-carboxyethyl group, a 3-carboxypropyl group, a 4-carboxybutyl group, or a 5-carboxypentyl group. [ka] It is. The C1-C6 alkylsulfonyl group is a straight-chain or branched-chain alkylsulfonyl group containing 1 to 6 carbon atoms, such as a methanesulfonyl group, an ethanesulfonyl group, or a propanesulfonyl group.

[0106] The C1-C6 haloalkylsulfonyl group is a linear or branched alkylsulfonyl group containing 1 to 6 carbon atoms in which one or more hydrogen atoms are substituted with the same or different halogen atoms, such as a trifluoromethanesulfonyl group. An amino group substituted with a C1-C6 alkyl group means an amino group in which one or two hydrogen atoms are substituted with the same or different C1-C6 alkyl groups or C1-C6 alkanoyl groups, for example, -NHMe or -NEt2.

[0107] The C3-C6 cycloalkyl group is a saturated cyclic hydrocarbon group containing 3 to 6 carbon atoms, such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and the like. The C3-C6 cycloalkyloxy group is a saturated cyclic hydrocarbon group containing 3 to 6 carbon atoms, such as a cyclopropyloxy group, a cyclobutyloxy group, a cyclopentyloxy group, and a cyclohexyloxy group.

[0108] C2-C 10An ester group is a saturated or unsaturated, straight or branched chain ester group containing 2-10 carbon atoms, such as, for example, -COO-(C1-C9 alkyl group), -COO-(C2-C8 alkenyl group) or -COO-(C3-C9 cycloalkyl group), or -O-CO-(C1-C9 alkyl group), -O-CO-(C2-C8 alkenyl group) or -O-CO-(C3-C9 cycloalkyl group), where said alkyl group, alkenyl group or cycloalkyl group may be substituted or unsubstituted (e.g., halogen substituted).

[0109] Cyclic bisbenzylisoquinoline compounds Cyclic bisbenzylisoquinoline alkaloids are very important natural products with a wide range of biological activities, and representative substances include oxyacanthine, tetrandrine, cepharanthine, fangchinoline, etc. [ka]

[0110] Oxyacanthine is a white crystalline, bitter powder. Its melting point is 216-217 °C, and its optical rotation is +131.5° (chloroform). It is practically insoluble in water, but dissolves in ethanol, chloroform, ethyl ether, and dilute acid. It is present in the roots of Berberis vulgaris, a plant of the Berberidaceae family, and Thalictrum lucidum, a plant of the Ranunculaceae family. Oxyacanthine has antibacterial, antihypertensive, choleretic, and anti-leukemic effects.

[0111] Compounds of the Invention The compound of the present invention is a cyclic bisbenzyltetrahydroisoquinoline compound represented by formula I or a pharma- ceutically acceptable salt thereof, or an enantiomer, diastereomer, racemate, crystal hydrate, solvate, or mixture thereof, and is the cyclic bisbenzyltetrahydroisoquinoline compound represented by formula (I). [ka] (In the formula, R1 and R2 are as defined above.) Suitably, the compounds of formula I of the present invention are not naturally occurring compounds.

[0112] In the present invention, the inventors unexpectedly found that when the compound does not contain a phenolic hydroxy group, the inhibitory activity against coronavirus SARS-CoV-2 is significantly improved, and the EC 50 The EC value is for oxyacanthin hydrochloride. 50 was found to be approximately 10 times lower than the original value. Preferably, the compound of the present invention is selected from Table A. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5]

[0113] More preferably, the compounds of the invention are selected from Table AI. [Table 2-1] [Table 2-2]

[0114] The "pharmaceutically acceptable salt" is a normal non-toxic salt formed by reacting the active compound of the present invention with an inorganic or organic acid. For example, a normal non-toxic salt can be prepared by reacting the active compound of the present invention with an inorganic or organic acid, and the inorganic acid includes hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, aminosulfonic acid, phosphoric acid, etc., and the organic acid includes citric acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, ethanesulfonic acid, naphthalenedisulfonic acid, maleic acid, malic acid, malonic acid, fumaric acid, succinic acid, propanoic acid, oxalic acid, trifluoroacetic acid, stearic acid, pamoic acid, hydroxymaleic acid, phenylacetic acid, benzoic acid, salicylic acid, glutamic acid, ascorbic acid, p-aminobenzenesulfonic acid, 2-acetyloxybenzoic acid, hydroxyethanesulfonic acid, etc., or the active compound of the present invention is a protic acid. The active compounds of the present invention may also be sodium, zinc, potassium, calcium, aluminum or ammonium salts which form esters with panic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, aspartic acid or glutamic acid and further form inorganic bases, or the active compounds of the present invention may form esters with lysine, arginine or ornithine and further form corresponding inorganic acid salts with hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid or phosphoric acid, or the active compounds of the present invention may form corresponding organic acid salts with formic acid, acetic acid, picric acid, methanesulfonic acid or ethanesulfonic acid, or the active compounds of the present invention may form sodium, zinc, potassium, calcium, aluminum or ammonium salts which form carboxyl groups / phenolic hydroxyl groups in the molecules of the active compounds of the present invention and inorganic bases.

[0115] The active ingredient of the present invention is also particularly suitable for use in combination with other anti-coronavirus drugs. Other representative anti-coronavirus drugs include interferon, RNA-dependent RNA polymerase inhibitors (e.g., Remdesivir (GS-5734), favipiravir, Galidesivir, GS-441524, Molnupiravir (EIDD-2801), NHC (EIDD-1931)), 3CL protease inhibitors (Nirmatrelvir, Ensitrelvir, GC-376), Lopinavir, Ritonavir, Nelfinavir, Chloroquine, Hydroxychloroquine, Cyclosporine, Carrimycin, Baicalin, Baicalein, Nafp ... These include, but are not limited to, naphthoquine, ciclesonide, ribavirin, penciclovir, leflunomide, teriflunomide, nafamostat, nitazoxanide, darunavir, arbidol, camostat, niclosamide, ivermectin, baricitinib, ruxolitinib, dasatinib, saquinavir, beclabuvir, simeprevir, or a pharma- ceutically acceptable salt thereof, or a combination thereof. The interferon includes one or more of interferon alpha-2a, interferon alpha-2b, interferon alpha-n1, interferon alpha-n3, interferon beta-1a, interferon beta-1b.

[0116] In addition, since SARS-CoV-2 infection causes acute lung injury, inflammatory responses, and thus cytokine storms, the active ingredient of the present invention is particularly suitable for use in combination with drugs that have an effect of improving acute lung injury, anti-inflammatory effects, or immunomodulatory effects. Representative drugs include, but are not limited to, zinc, fingolimod, vitamin C, olmesartan medoxomil, valsartan, losartan, thalidomide, glycyrrhizic acid, artemisinin, dihydroartemisinin, artesunate, artemisone, azithromycin, escin, and naproxen.

[0117] Preferably, the active ingredient of the present invention is combined with artemisinin-based drugs (one or more of artemisinin, dihydroartemisinin, artesunate, artemisone). A large amount of research has shown that artemisinin-based drugs have multiple anti-inflammatory and immunoregulatory mechanisms, and can suppress the proliferation and activation of T cells, inhibit the activation of B cells and the production of antibodies, increase regulatory T cells, and reduce the release of inflammatory cytokines, thereby achieving anti-inflammatory and immunoregulatory functions, and is expected to alleviate the immune damage symptoms caused by novel coronavirus (SARS-CoV-2) infection.

[0118] Preferably, the active ingredient of the present invention is used in combination with an artemisinin drug (one or more of artemisinin, dihydroartemisinin, artesunate, artemisone) or azithromycin. The active ingredient of the present invention can inhibit the infection activity of novel coronaviruses such as SARS-CoV-2. Therefore, when the active ingredient of the present invention is applied or administered in treatment, it can inhibit the infection of the 2019 novel coronavirus (SARS-CoV-2) and even achieve an antiviral effect.

[0119] Manufacturing method The method for producing the cyclic bisbenzyltetrahydroisoquinoline compound of the present invention is one or more methods selected from the following: a) using a cyclic bisbenzylisoquinoline containing a phenolic hydroxy group as a raw material, the cyclic bisbenzylisoquinoline compound is obtained by alkylating the raw material with an alkylating agent; b) using a cyclic bisbenzylisoquinoline containing a phenolic hydroxy group as a raw material, an acylation reaction with an acylating agent to obtain the cyclic bisbenzylisoquinoline compound; In another preferred embodiment, the method uses oxyacanthin as a raw material, and subjecting it to a condensation acylation reaction with a carboxylic acid to obtain the cyclic bisbenzylisoquinoline compound.

[0120] In another preferred embodiment, the condensation acylation reaction is carried out in the presence of a condensing agent, which includes, but is not limited to, N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), and the like. c) reacting oxyacanthin with a sulfonylating agent in the presence of a base to obtain compound (I-1b); (I-1b) is subjected to a coupling reaction with a coupling reagent to obtain a cyclic bisbenzylisoquinoline compound represented by formula I-1, which is shown in reaction scheme 1; [ka] (In formula I-1, R1 is selected from hydrogen, halogen, a C1-C6 alkylthio group, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, an amino group substituted with a C1-C6 alkyl group, a cyano group, a carboxy group, an aldehyde group, and a C1-C6 alkanoyl group. L in formula 1-1b is a leaving group, for example, selected from a C1-C6 alkylsulfonyloxy group, a C1-C6 haloalkylsulfonyloxy group, a benzenesulfonyloxy group, a naphthalenesulfonyloxy group, and preferably a methanesulfonyloxy group and a trifluoromethanesulfonyloxy group. d) As shown in the following reaction scheme 2, oxyacanthin is used as a raw material to produce the compound of formula (I-2) through nitration, reduction and ring-closing reactions; [ka] (In formula I-2, R1 and R2 together with the adjacent benzene ring form a benzo[5-6 membered monocyclic heterocycle] which is unsubstituted or substituted with 1-4 substituents.)

[0121] In another preferred embodiment, the benzo[5-6 membered monocyclic heterocycle] is [ka] Selected from. In another preferred embodiment, the substituent is selected from halogen, a hydroxy group, a mercapto group, an amino group, an oxo (=O), a thio (=S), and a C1-C6 alkyl group, and the heterocycle contains 1 to 3 heteroatoms selected from N, O, and S.

[0122] e) As shown in reaction scheme 3, oxyacanthin is used as a raw material to produce the compound of formula (I-3) through a multi-step reaction; [ka] (In formula I-3, R1 and R2 together with the adjacent benzene ring form a benzo[5-6 membered monocyclic heterocycle] which is unsubstituted or substituted with 1 to 4 substituents. The substituent of the substitution is selected from a halogen, a hydroxy group, a mercapto group, an amino group, an oxo (=O), a thio (=S), and a C1 to C6 alkyl group. The heterocycle contains 1 to 3 heteroatoms selected from N, O and S.

[0123] In another preferred embodiment, the benzo[5-6 membered monocyclic heterocycle] is [ka] Selected from. (In formula I-3b, L is a leaving group, for example, a C1-C6 alkylsulfonyloxy group, a C1-C6 haloalkylsulfonyloxy group, a benzenesulfonyloxy group, a naphthalenesulfonyloxy group, preferably a methanesulfonyloxy group or a trifluoromethanesulfonyloxy group.)

[0124] In another preferred embodiment, the method e) comprises the steps of: e1) subjecting a compound of formula (I-1a) to an ortho-nitration reaction with a nitrating agent to produce a compound of formula (I-3a); e2) reacting the compound of formula (I-3a) with a sulfonylating agent in the presence of a base in a suitable solvent to obtain a compound of formula (I-3b); e3) compound of formula (I-3b) is reacted with benzylamine in a Buchwald-Hartwig reaction to obtain compound of formula (I-3c); e4) subjecting the compound of formula (I-3c) to a reduction reaction to obtain a compound of formula (I-3d); e5) Compound (I-3) is obtained by subjecting compound (I-3d) to a ring-closing reaction.

[0125] f) The compound obtained by any one of methods a) to e) is subjected to functional group conversion to obtain the cyclic bisbenzylisoquinoline compound.

[0126] Drug Compositions and Uses The present invention also provides use of a mixture of one or more of the active compounds of formula I, or pharma- ceutically acceptable salts thereof, or prodrugs thereof, which inhibit the replication of the coronavirus of the present invention, as active ingredients, for the manufacture of a medicament for treating and / or preventing or alleviating associated diseases, such as respiratory infections and pneumonia, caused by infection with a coronavirus, such as the 2019 novel coronavirus.

[0127] The pharmaceutical composition provided by the present invention preferably contains an active ingredient in a weight ratio of 0.001-99 wt%, and the preferred ratio is that the active compound of the present invention accounts for 0.1 wt-90 wt or 1 wt%-50 wt% of the total weight as the active ingredient, with the remainder being a pharma- ceutically acceptable carrier, diluent or solution or salt solution. If necessary, the drug of the present invention may further contain one or more pharma- ceutically acceptable carriers, including diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption enhancers, surfactants, adsorption carriers, lubricants, etc., commonly used in the pharmaceutical field.

[0128] The compounds and pharmaceutical compositions provided by the present invention may be in a variety of forms, for example, tablets, capsules, powders, syrups, solutions, suspensions, and aerosols, and may be present in suitable solid or liquid carriers or diluents, and in suitable sterile equipment for injection or infusion. Various dosage forms of the pharmaceutical composition of the present invention can be prepared according to conventional manufacturing methods in the pharmaceutical field. The unit dose of the formulation usually contains 0.05-400 mg of the active compound of the present invention, preferably 1 mg-500 mg of the active compound of the present invention.

[0129] The compounds and pharmaceutical compositions of the present invention can be used clinically in mammals, including humans and animals, and can be administered via oral, nasal, cutaneous, pulmonary or gastrointestinal routes. Oral administration is the most preferred. The most preferred daily dosage is 0.01 mg to 400 mg / kg body weight, administered in one dose, or 0.01 mg to 200 mg / kg body weight, administered in several doses. Regardless of which administration method is used, the optimal dosage for an individual is determined by the specific treatment. Usually, a small dosage is administered first, and then gradually increased until the optimal dosage is found.

[0130] The drugs or inhibitors of the present invention can be administered in a variety of forms, for example, by injection, spray, nasal drops, eye drops, penetration, absorption, physical or chemical methods, and can be introduced into the body, for example, into muscle, intradermal, subcutaneous, venous, or mucosal tissue, or mixed or embedded in other substances. Typically, the active ingredient of the present invention or a pharmaceutical composition containing it can be administered in the form of a unit dosage, and the route of administration can be enteral or parenteral, for example, oral administration, intravenous injection, intramuscular injection, subcutaneous injection, nasal cavity, oral mucosa, ophthalmic, pulmonary and respiratory tract, skin, vagina, rectum, etc.

[0131] The dosage form may be a liquid dosage form, a solid dosage form or a semi-solid dosage form. The liquid dosage form may be a solution (including true solution and colloid solution), an emulsion (including o / w type, w / o type and multiple emulsion), a suspension, an injection (including aqueous injection, powder injection and infusion), an eye drop, a nose drop, a lotion and a pour-on, etc., the solid dosage form may be a tablet (normal tablet, enteric-coated tablet, troche tablet, dispersible tablet, chewable tablet, effervescent tablet, oral disintegrating tablet), a capsule (hard capsule, soft capsule, enteric capsule), a granule, a powder, a micro pill, a drop pill, a suppository, a membrane, an adhesive sheet, an aerosol (powder inhalant), a spray, etc., and the semi-solid dosage form may be an ointment, a gel, a paste, etc. The active ingredients of the present invention may be formulated into conventional, sustained release, controlled release, targeted release and various particulate delivery systems.

[0132] A wide variety of excipients known in the art can be used to tablet the active ingredient of the present invention, including diluents, binders, wetting agents, disintegrants, lubricants, and flow agents. The diluent may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent may be water, ethanol, isopropanol, etc.; the binder may be starch paste, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, gum arabic paste, gelatin paste, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, ethylcellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropylcellulose, crospovidone, croscarmellose sodium, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfonate, etc.; the lubricant and flow agent may be talc powder, silica, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.

[0133] The tablets may also be further coated, for example, sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-coated and multiple-coated tablets. To make the dosage unit into a capsule, the active ingredient of the present invention can be mixed with a diluent and a fluidizer, and the mixture can be placed directly into a hard or soft capsule. The active ingredient can also be first granulated or pelletized with a diluent, a binder, and a disintegrant, and then placed into a hard or soft capsule. The types of diluents, binders, wetting agents, disintegrants, and fluidizers used to prepare the tablets of the present invention can also be used to prepare the capsules of the present invention.

[0134] In order to prepare the active ingredient of the present invention into an injection, water, ethanol, isopropanol, propylene glycol or a mixture thereof can be used as a solvent, and an appropriate amount of a compatible agent, a dissolving agent, a pH adjuster, or an osmotic pressure adjuster commonly used in this field can be added. The compatible agent or dissolving agent can be poloxamer, lecithin, hydroxypropyl-β-cyclodextrin, etc., the pH adjuster can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc., and the osmotic pressure adjuster can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. When preparing a freeze-dried powder injection, mannitol, glucose, etc. can also be added as a carrier.

[0135] If necessary, coloring agents, preservatives, flavorings, taste-correcting agents or other additives may be added to the drug formulation. The active ingredients or compositions of the present invention may be used alone or in combination with other therapeutic agents or indications. When the active ingredient of the present invention synergizes with other therapeutic agents, the dosage should be adjusted according to the actual situation.

[0136] The main advantages of the present invention are: 1) The compounds of the present invention have good inhibitory activity against coronavirus replication, and some compounds have an EC value of 1.0 or higher for the inhibitory effect against coronavirus RNA replication. 50 reaches levels of <1 μM. 2) The compounds of the present invention do not contain phenolic hydroxyl groups, and not only have significantly improved anti-coronavirus SARS-CoV-2 activity, but also have good physical and chemical properties, good metabolic properties, and high bioavailability upon oral administration. 3) The compounds of the present invention are expected to have good selectivity for the hERG ion channel and the Nav1.5 ion channel, and to have low toxicity and side effects on the heart. 4) The compounds of the present invention have the characteristics of strong activity, large therapeutic index (SI), effective oral administration, low effective dose, and low toxicity and side effects, and are useful for the prevention and / or treatment of coronavirus infection-related diseases, and have good prospects for clinical application. 5) The compound of the present invention also has therapeutic effects on diseases associated with viral infection, diseases associated with inflammation (pneumonia, non-alcoholic steatohepatitis, colitis, nephritis, pancreatitis, myocarditis, arthritis, inflammatory pain), diseases associated with fibrosis (pulmonary fibrosis, silicosis, liver fibrosis, kidney fibrosis, myocardial fibrosis, skin fibrosis, retinal fibrosis, bone marrow fibrosis), autoimmune diseases associated with abnormal differentiation of Th1 and / or Th17 (psoriasis, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, neuromyelitis optica, myasthenia gravis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, delayed hypersensitivity reaction, graft-versus-host disease, etc.), osteoporosis, and neurodegenerative diseases.

[0137] The present invention will be further described below with reference to specific examples. It is understood that these examples are only used to illustrate the present invention and do not limit the scope of the present invention. Experimental methods for which no specific conditions are given in the following examples are generally performed according to standard conditions, such as those described in Sambrook et al., "Molecular Cloning: A Laboratory Manual" (New York, Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer's recommended conditions. Unless otherwise stated, percentages and parts are by weight.

[0138] Example 1 Preparation of Compound 1 [ka] The procedure is as follows: [ka]

[0139] Step 1: In a 50 mL round-bottom single-neck flask, oxyacanthine hydrochloride (1.2 g, 1.76 mmol) was added, followed by dichloromethane (12 mL) and triethylamine (0.89 g, 8.80 mmol, 5 eq). The mixture was stirred in an ice bath for 10 min, trifluoromethanesulfonic anhydride (0.58 mL, 3.45 mmol, 1.96 eq) was slowly added dropwise, and the mixture was stirred at room temperature for 2 h. TLC showed that the starting material was completely converted. 1 N hydrochloric acid (5.3 mL) was added, the mixture was stirred, and the organic layer was separated. The organic layer was further washed once with a saturated aqueous solution of sodium bicarbonate, dried over anhydrous sodium sulfate, concentrated, and subjected to silica gel column chromatography to obtain a pale yellow solid 1-a (1.08 g, 1.46 mmol), with a yield of 83%. 1 H NMR (600 Mhz, acetone-d6) δ 7.50 (dd, J = 8.5, 2.3 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 7.06 (dd, J = 8.2, 2.3 Hz, 1H), 7.00 (dd, J = 8.4, 2.6 Hz, 1H), 6.94 (dd, J = 8.3, 2.0 Hz, 1H), 6.71 (s, 1H), 6.49 (s, 1H), 6.46 (s, 1H), 6.33 (dd, J = 8.2, 2.7 Hz, 1H), 5.66 (d, J = 2.0 Hz, 1H), 4.09 (d, J = 5.4 Hz, 1H), 3.76 (s, 3H), 3.68 (s, 3H), 3.62 (d, J = 3.5 Hz, 1H), 3.31 (d, J = 14.5 Hz, 1H), 3.24 (dd, J = 14.0, 4.1 Hz, 1H), 3.16 (s, 3H), 3.15 - 3.10 (m, 1H), 3.01 - 2.88 (m, 2H), 2.86 - 2.79 (m, 2H), 2.77 - 2.71 (m, 1H), 2.63 (dd, J = 5.2, 1.8 Hz, 1H), 2.60 (s, 3H), 2.56 (s, 3H), 2.37 - 2.20 (m, 3H). ESI-MS (m / z): 741.38 [MH].

[0140] Step 2: 1-a (850 mg, 1.15 mmol) was mixed with N,N-dimethylacetamide (10 mL), and zinc cyanide (200 mg, 1.70 mmol, 1.48 eq), tris(dibenzylideneacetone)dipalladium (55 mg, 0.06 mmol, 0.05 eq), 1,1'-bis(diphenylphosphino)ferrocene (65 mg, 0.12 mmol, 0.1 eq) and zinc powder (12 mg, 0.18 mmol, 0.16 eq) were added in that order. The atmosphere was replaced with nitrogen gas four times, and the temperature was raised to 140-150 °C for 2 h. The reaction was continued for 3 h, and TLC showed that the raw materials were completely converted. The reaction solution was cooled to 30-40°C, diluted with ethyl acetate, and filtered to remove insoluble matter. The filtrate was washed three times with 5% aqueous sodium bicarbonate solution, and the ethyl acetate layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 1 (583 mg, 0.94 mmol) as a pale yellow solid in a yield of 82%. 1H NMR (600 Mhz, acetone-d6) δ 7.51 - 7.45 (m, 2H), 7.07 (dd, J = 8.2, 2.3 Hz, 1H), 7.01 (dd, J = 8.4, 2.6 Hz, 1H), 6.98 (dd, J = 8.0, 1.4 Hz, 1H), 6.70 (s, 1H), 6.48 (s, 1H), 6.45 (s, 1H), 6.34 (dd, J = 8.2, 2.7 Hz, 1H), 5.60 (d, J = 1.4 Hz, 1H), 4.09 (d, J = 5.4 Hz, 1H), 3.76 (s, 3H), 3.69 (s, 3H), 3.67 (m, 1H), 3.35 - 3.25 (m, 2H), 3.15 (s, 3H), 3.13 - 3.07 (m, 1H), 3.02 - 2.88 (m, 2H), 2.89 - 2.78 (m, 2H), 2.73 (m, 1H), 2.63 (m, 1H), 2.60 (s, 3H), 2.56 (s, 3H), 2.38 - 2.19 (m, 3H). ESI-MS (m / z): 618.37 [MH].

[0141] Example 2 Preparation of Compound 2 [ka] 500 mg of oxyacanthine hydrochloride was suspended in acetonitrile (12 mL), triethylamine (260 mg) was added at room temperature, and 114 mg of n-butyl isocyanate was slowly added dropwise to the reaction solution. The mixture was stirred at 25-28°C for 2-3 hours, diluted with ethyl acetate, washed three times with water, and the organic layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain 385 mg of the title compound 2 as a pale yellow solid with a yield of 74%. 1H NMR (600 Mhz, アセトン-d6) δ 7.43 (dd, J = 8.4, 2.4 Hz, 1H), 6.96 (dd, J = 8.2, 2.3 Hz, 1H), 6.92 (dd, J = 8.3, 2.6 Hz, 1H), 6.88 (d, J = 8.1 Hz, 1H), 6.79 (dd, J = 8.2, 2.0 Hz, 1H), 6.68 (s, 1H), 6.47 (s, 1H), 6.44 (s, 1H), 6.26 (dd, J = 8.2, 2.6 Hz, 1H), 5.55 (d, J = 2.1 Hz, 1H), 4.08 (d, J = 5.0 Hz, 1H), 3.76 (s, 3H), 3.67 (s, 3H), 3.57 (m, 1H), 3.30 - 3.10 (m, 5H), 3.16 (s, 3H), 2.96 (m, 1H), 2.89 - 2.60 (m, 5H), 2.59 (s, 3H), 2.55 (s, 3H), 2.38 - 2.28 (m, 3H), 1.51 (p, J=7.1 Hz, 2H), 1.36 (h, J=7.4 Hz, 2H), 0.87 (t, J=7.3 Hz, 3H). ESI-MS (m / z): 708.49 [MH].

[0142] Example 3 Production of Compound 3

change

change

[0143] Project 1: Compound 1 (1.1 g, 1.78 mmol) was mixed with ethylene glycol (11 mL), potassium hydroxide (600 mg, 10.70 mmol, 6 eq) and water (0.5 mL) were added, and the mixture was purged with nitrogen gas several times. The mixture was heated to 150°C and reacted for 7 h. The reaction solution was cooled to room temperature, diluted with water (25 mL), and adjusted to pH 7-8 with dilute hydrochloric acid. Dichloromethane was added for extraction. The organic phase was separated, washed once with water, washed once with saline, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain compound 3-a (300 mg) as a pale yellow solid in 26% yield. 1 H NMR (600 MHz, chloroform-d) δ 7.67 (d, 1H), 7.48 (d, 1H), 6.92 (m, 1H), 6.80 (m, 1H), 6.58 (s, 1H), 6.55 (m, 1H), 6.36 (s, 1H), 6.20 (s, 1H), 6.06 (d, 1H), 5.51 (s, 1H), 4.45 (d, 1H), 3.98 (m, 1H), 3.78 (s, 3H), 3.59-3.39 (m, 2H), 3.50 (s, 3H), 3.36-3.20 (m, 2H), 3.17 (s, 3H), 3.14-3.00 (m, 2H), 2.90-2.62 (m, 4H), 2.75 (s, 3H), 2.57 (s, 3H), 2.43-2.25 (m, 2H). ESI-MS (m / z): 637.36 [MH], 635.37 [M - H] - .

[0144] Step 2: Compound 3-a (600 mg, 0.94 mmol) was mixed with methanol (6 mL), and concentrated sulfuric acid (352 mg, 3.59 mmol, 3.8 eq) was added at room temperature. After the addition was completed, the mixture was heated to reflux and reacted for 7 h. TLC showed that the raw material was completely converted. Sodium bicarbonate (938 mg, 11.8 eq) was added and stirred for 10 min. Diluted with dichloromethane, and stirred with water to separate the layers. The organic phase was separated, washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 3 (486 mg), which was an off-white solid, in 80% yield. 1 H NMR (600 MHz, chloroform-d) δ 7.70 (d, 1H), 7.45 (brs, 1H), 6.95 (m, 2H), 6.89 (d, 1H), 6.60 (s, 1H), 6.35 (s, 1H), 6.30 (dd, 1H), 6.30 (s, 1H), 5.57 (m, 1H), 4.22 (brs, 1H), 3.85 (s, 3H), 3.78 (s, 3H), 3.70 (m, 1H), 3.61 (s, 3H), 3.47-3.20 (m, 3H), 3.17 (s, 3H), 3.10-2.95 (m, 2H), 2.88-2.65 (m, 4H), 2.68 (s, 3H), 2.57 (s, 3H), 2.46-2.22 (m, 3H). ESI-MS (m / z): 651.47 [MH].

[0145] Example 4 Preparation of Compound 4 [ka] Compound 1 (1.1 g, 1.78 mmol) was suspended in t-butanol (8 mL), potassium t-butoxide (1.4 g, 12.48 mmol, 7 eq) was added, and the temperature was raised to 80°C to react until the raw materials were completely converted. The reaction solution was cooled to room temperature and then concentrated to remove most of the t-butanol. Water and ethyl acetate were added to the remaining solution, and the solution was stirred to separate the layers. The ethyl acetate layer was separated, washed once with brine, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 4 (820 mg), which was a pale yellow solid with a yield of 73%. 1 H NMR (600 Mhz, acetone-d6) δ 7.90 (d, J = 8.0 Hz, 1H), 7.57 (brs, 1H), 7.49 (dd, J = 8.4, 2.3 Hz, 1H), 7.03 (td, J = 8.0, 2.4 Hz, 2H), 6.96 (dd, J = 8.0, 1.6 Hz, 1H), 6.69 (m, 1H), 6.68 (s, 1H), 6.47 (s, 1H), 6.45 (s, 1H), 6.32 (dd, J = 8.2, 2.7 Hz, 1H), 5.63 (d, J = 1.5 Hz, 1H), 4.09 (d, J = 5.3 Hz, 1H), 3.76 (s, 3H), 3.68 (s, 3H), 3.63 (m, 1H), 3.33 - 3.22 (m, 2H), 3.16 (s, 3H), 3.12 (m, 1H), 2.97 (m, 1H), 2.89 (dd, J = 2.82 (m, 2H), 2.73 (m, 1H), 2.62 (m, 1H), 2.60 (s, 3H), 2.56 (s, 3H), 2.37 - 2.24 (m, 3H). 636.38 [MH].

[0146] Example 5 Preparation of Compound 5 [ka] Compound 3-a (300 mg, 0.47 mmol) was mixed with tetrahydrofuran (2 mL), CDI (230 mg, 1.42 mmol) was added at room temperature, and the mixture was stirred at room temperature for 30 min. 28% aqueous methylamine solution (468 mg, 4.23 mmol) was added to the reaction solution. After the addition was completed, the mixture was stirred for 30 min. The reaction solution was poured into water, and ethyl acetate was added for extraction. The organic layer was separated, concentrated, and subjected to silica gel column chromatography to obtain the title compound 5 (230 mg) as a pale yellow solid in 75% yield. 1 H NMR (600 MHz, chloroform-d) δ 8.03 (d, 1H), 7.79 (q, 1H), 7.50 (m, 1H), 7.00 (m, 3H), 6.59 (s, 1H), 6.34 (s, 1H), 6.31 (m, 2H), 5.56 (d, 1H), 4.15 (d, 1H), 3.80 (s, 3H), 3.68 (t, 1H), 3.61 (s, 3H), 3.40-3.38 (m, 1H), 3.35-3.22 (m, 2H), 3.17 (s, 3H), 3.03 (m, 1H), 2.99 (m, 3H), 2.98-2.82 (m, 3H), 2.70 (m, 2H), 2.65 (s, 3H), 2.55 (s, 3H), 2.45-2.22 (m, 3H). ESI-MS (m / z): 650.3 [M + H] + .

[0147] Example 6 Preparation of Compound 6 [ka] Compound 3-a (600 mg, 0.94 mmol) was dissolved in dichloromethane (5 mL), N,N-dimethylformamide (8 μL) was added, and oxalyl chloride (0.4 mL, 4.72 mmol) was added dropwise at ambient temperature. After the addition was completed, the reaction solution was concentrated to dryness under the protection of nitrogen gas, and then stirred for 40 min. The reaction solution was then dissolved in dichloromethane (5 mL), and the solution was added dropwise to a solution of cyclopropylamine (330 μL, 4.76 mmol) in dichloromethane (4 mL) at ambient temperature. After the addition was completed, the solution was stirred for 30 min. A saturated aqueous solution of ammonium chloride (10 mL) was added and stirred to separate the layers. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 6 (504 mg, 0.75 mmol), which was a pale yellow solid with a yield of 79%. 1 H NMR (600 MHz, chloroform-d) δ 8.07 (d, 1H), 7.83 (m, 1H), 7.64 (m, 1H), 6.95 (m, 3H), 6.60 (s, 1H), 6.36 (s, 1H), 6.30 (s, 1H), 6.27 (dd, 1H), 5.52 (d, 1H), 4.30 (m, 1H), 3.78 (s, 3H), 3.71 (m, 1H), 3.61 (s, 3H), 3.55 (m, 1H), 3.42-3.20 (m, 2H), 3.17 (s, 3H), 3.15-3.00 (m, 2H), 2.90-2.82 (m, ESI-MS (m / z): 676.58 [M + H] + .

[0148] Example 7 Preparation of Compound 7 [ka] The preparation method of compound 7 (ie, compound 3-a) has already been described in Example 3.

[0149] Example 8 Preparation of Compound 8 [ka] Compound 1 (500 mg, 0.81 mmol), formic acid (15 mL), and Raney nickel (1.03 g) were placed in a 50 mL round-bottom single-neck flask, purged with nitrogen gas, and heated to 80-90 °C for 1-2 h. After TLC showed complete conversion of the raw materials, the reaction solution was cooled to ambient temperature, filtered to remove insoluble matter, concentrated and dried, diluted with dichloromethane, washed with aqueous sodium bicarbonate, and the organic layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 8 (248 mg, 0.4 mmol) as a yellow solid in 49% yield. ESI-MS (m / z): 621.37 [MH].

[0150] Example 9 Preparation of Compound 9 [ka] Compound 8 (80 mg, 0.13 mmol) was dissolved in 1 mL of methanol, cooled to 5-10°C in an ice bath, sodium borohydride (9.3 mg, 0.245 mmol, 1.9 eq) was added, and after the addition was complete, the mixture was slowly warmed to ambient temperature. After 1 h, TLC showed complete conversion of the raw material, and the reaction was quenched by carefully adding a saturated aqueous solution of ammonium chloride dropwise, and dichloromethane and water were added, stirred and separated. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 9 (52 mg, 0.084 mmol) as a pale yellow solid in 64% yield. ESI-MS (m / z): 623.38 [MH].

[0151] Example 10 Preparation of Compounds 10 and 33 [ka] 1-a (250 mg, 0.34 mmol), palladium acetate (12 mg, 0.05 mmol, 0.15 eq), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (49 mg, 0.10 mmol, 0.3 eq), cesium carbonate (328 mg, 1.00 mmol, 3 eq), and benzylamine (75 μL, 0.69 mmol, 2 eq) were mixed in dioxane (4 mL), purged with nitrogen gas three times, heated to 100-105°C, and reacted for 14 hours. TLC showed that the raw materials had completely reacted, and the reaction solution was cooled to room temperature, filtered through diatomaceous earth, and the filter residue was washed with ethyl acetate. Water and ethyl acetate were added to the filtrate, and the mixture was stirred to separate the layers. The ethyl acetate layer was separated, washed once with brine, dried over anhydrous sodium sulfate, concentrated, and subjected to silica gel column chromatography to obtain the title compound 10 (192 mg) as a pale yellow solid in 82% yield. ESI-MS (m / z): 698.47 [MH].

[0152] [ka] Similarly, further separation during silica gel column chromatography afforded compound 33 (10 mg) as the main by-product, a pale yellow solid, with a yield of 5%. ESI-MS (m / z): 593.48 [MH].

[0153] Example 11 Preparation of Compound 11 [ka] Compound 10 (190 mg, 0.27 mmol), palladium on carbon (17 mg), ammonium formate (170 mg), and methanol (3 mL) were placed in a 25 mL round-bottom single-neck flask, and the mixture was purged with nitrogen gas twice. The mixture was heated and refluxed for 4-5 hours. TLC showed that the raw materials had completely reacted, and the mixture was filtered through diatomaceous earth, the filter residue was washed with ethyl acetate, water and ethyl acetate were added to the filtrate, and the mixture was stirred to separate the layers. The ethyl acetate layer was separated, washed once with brine, dried over anhydrous sodium sulfate, concentrated, and subjected to silica gel column chromatography to obtain the title compound 11 (114 mg) as an off-white solid in 69% yield. ESI-MS (m / z): 608.38 [MH].

[0154] Example 12 Preparation of Compounds 12 and 14 [ka] The process is as follows. [ka]

[0155] Step 1: Compound 11 dihydrochloride (300 mg, 0.44 mmol) was mixed with ethyl formate (10 mL), triethylamine (400 mg, 3.95 mmol, 9 eq) was added at room temperature, and the mixture was allowed to react overnight under reflux. TLC showed complete conversion of the raw materials, and the reaction mixture was cooled to room temperature, and then 0.5 N dilute hydrochloric acid (7 mL) was added and stirred to separate the layers. The organic layer was separated, washed with brine, concentrated, and subjected to silica gel column chromatography to obtain compound 14 (216 mg), an off-white solid, in 77% yield. ESI-MS (m / z): 636.37 [MH].

[0156] Step 2: Compound 14 (100 mg, 0.157 mmol) was suspended in dry tetrahydrofuran (1.2 mL), and borane-tetrahydrofuran (1 M THF solution, 0.79 mL, 5 eq) was added dropwise in an ice bath. After the addition was completed, the mixture was heated to reflux under nitrogen gas protection. After the raw material was completely converted by TLC, the mixture was cooled to room temperature and placed in an ice bath for 10 min. Methanol was carefully added dropwise while stirring. When gas generation ceased, excess methanol and concentrated hydrochloric acid (95 μL) were added and the mixture was refluxed for 3 h. The reaction solution was concentrated, and the remaining liquid was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 12 (55 mg), which was an off-white solid in 56% yield. ESI-MS (m / z): 622.48 [MH].

[0157] Example 13 Preparation of Compound 13 [ka] Compound 11 dihydrochloride (150 mg, 0.220 mmol) was dissolved in pyridine (2.0 mL) and acetyl chloride (41 μL, 0.57 mmol, 2.6 eq) was added dropwise at ambient temperature. After the addition was completed, the mixture was heated to 60° C. and reacted for 2-3 h. The reaction solution was concentrated and subjected to silica gel column chromatography to give the title compound 13 (135 mg) as an off-white solid in 95% yield. ESI-MS (m / z): 650.48 [MH].

[0158] Example 14 Preparation of Compound 15 [ka] Oxyacanthin hydrochloride (1.0 g, 1.47 mmol) was dissolved in acetic acid (8 mL) and concentrated nitric acid (65-68% nitric acid in water, 128 μL, 1.2 eq) was added dropwise at ambient temperature. After the addition was completed, the mixture was stirred at room temperature for 5 min. The reaction mixture was slowly poured into saturated aqueous sodium bicarbonate solution and stirred until gas generation ceased. Dichloromethane was added for extraction. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 15 (486 mg) as a yellow solid in 51% yield. ESI-MS (m / z): 654.36 [MH], 652.37 [M - H] - .

[0159] Example 15 Preparation of Compound 16 [ka] Compound 15 (525 mg, 0.80 mmol), 10% palladium on carbon (55 mg), ammonium formate (610 mg, 9.68 mmol, 12 eq), and methanol (12 mL) were placed in a 25 mL round-bottom single-neck flask, and the mixture was heated and refluxed for 1 h under nitrogen gas. TLC showed complete conversion of the starting material. Insoluble materials were removed by filtration, the filter residue was washed with methanol, and the filtrate was concentrated to a small volume. The residue was diluted with dichloromethane, washed with saturated aqueous sodium bicarbonate, washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to give the title compound 16 (360 mg) as a pale yellow solid in 72% yield. ESI-MS (m / z): 624.38 [MH].

[0160] Example 16 Preparation of Compound 17 [ka] The dihydrochloride salt of compound 16 (225 mg, 0.32 mmol) was dissolved in N,N-dimethylformamide (3 mL) and N,N'-carbonyldiimidazole (260 mg, 1.60 mmol, 5 eq) was added at room temperature and stirred at ambient temperature for 2 h. TLC showed complete conversion of the starting material. The reaction was poured into 12 mL of ice water and stirred for 10 min, filtered, the cake was washed twice with water and blow-dried at 50 °C for 6 h to give the title compound 17 (127 mg) as an off-white solid in 61% yield. 1 H NMR (500 MHz, chloroform-d) δ 7.45 (d, 1H), 6.90 (dd, 1H), 6.84 (dd, 1H), 6.69 (s, 1H), 6.60 (m, 1H), 6.44 (s, 1H), 6.40 (m, 1H), 6.35 (s, 1H), 5.31 (d, 1H), 4.23 (d, 1H), 3.77 (s, 3H), 3.67 (m, 1H), 3.62 (s, 3H), 3.34 (m, 1H), 3.24-3.13 (m, 3H), 3.22 (s, 3H), 3.05 - 2.91 (m, 3H), 2.90 - 2.81 (m, 2H), 2.71 (m, 1H), 2.66 (s, 3H), 2.64 (s, 3H), 2.56 - 2.45 (m, 2H). ESI-MS (m / z): 650.30 [MH].

[0161] Example 17 Preparation of Compound 18 [ka] The dihydrochloride salt of compound 16 (215 mg, 0.31 mmol) was dissolved in ethanol (3 mL) and trimethyl orthoformate (0.9 mL, 8.2 mmol, 27 eq) and p-toluenesulfonic acid monohydrate (60 mg, 0.32 mmol, 1 eq) were added at ambient temperature, and the mixture was purged with nitrogen gas three times and reacted at 65-70 °C for 14 h. TLC showed complete conversion of the raw material, and the mixture was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 18 (168 mg) as an off-white solid in 86% yield. ESI-MS (m / z): 634.48 [MH].

[0162] Example 18 Preparation of Compound 19 [ka] Under the protection of nitrogen gas, compound 1 (605 mg, 0.98 mmol) was dissolved in dry tetrahydrofuran (5 mL), placed in an ice bath for 5 min, slowly added methyllithium (1.53 mL, 1.6 M ethyl ether solution, 2.5 eq), and reacted for 80 min under ice bath conditions. The reaction solution was carefully poured into ice water, and then added with 2 N aqueous sulfuric acid to adjust the pH to 2-3. The mixture was stirred at ambient temperature for 1 h, and then added with sodium bicarbonate to adjust the pH to a weak base. The mixture was extracted with dichloromethane. The organic phase was separated, dried with anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 19 (143 mg), which was a pale yellow solid, with a yield of 23%. ESI-MS (m / z): 635.38 [MH].

[0163] Example 19 Preparation of Compound 21 [ka] 500 mg of oxyacanthine hydrochloride was suspended in dichloromethane (5 mL), and then thioctic acid (160 mg), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (220 mg), and 4-dimethylaminopyridine (15 mg) were added in that order, and the mixture was stirred at 23-25°C for 4-6 h. After the raw material was completely converted by TLC, 4 mL of water was added and the mixture was stirred and separated. The organic layer was separated, washed once with 2 mL of saturated saline, and the organic layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain 380 mg of the title compound 21, which was a pale yellow solid with a yield of 65%. ESI-MS (m / z): 797.48 [M + H] + .

[0164] Example 20 Preparation of Compound 22 [ka] The title compound 22 was obtained by reacting compound 7 with cyclopentylamine according to the method of Example 6. The compound was a pale yellow solid with a yield of 57%. ESI-MS (m / z): 704.48 [M + H] + .

[0165] Example 21 Preparation of Compound 27 [ka] The process is as follows. [ka]

[0166] Step 1: Compound 15 (950 mg, 1.45 mmol) was dissolved in dichloromethane (7 mL), pyridine (565 mg, 7.14 mmol, 4.9 eq) and 4-dimethylaminopyridine (14 mg, 0.115 mmol, 0.08 eq) were added, and the mixture was stirred in an ice bath for 5-10 min. Trifluoromethanesulfonic anhydride (0.49 mL, 2 eq) was added dropwise. After the addition was completed, the mixture was kept warm for 15 min. TLC showed that the raw material was completely converted. The mixture was washed with 0.5 N dilute hydrochloric acid, and the organic phase was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain product 27-a (800 mg), a yellow solid, in 70% yield. ESI-MS (m / z): 786.28 [MH].

[0167] Step 2: In a 10 mL round-bottom single-neck flask, 27-a (205 mg, 0.26 mmol), palladium acetate (7 mg, 0.12 eq), 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl (27 mg, 0.21 eq), formic acid (33 μL, 3.3 eq), N,N-diisopropylethylamine (152 μL, 3.3 eq), and dioxane (2.0 mL) were placed in order, and the atmosphere was replaced with nitrogen gas several times. The mixture was stirred at 85-90 °C for 50 min. TLC showed that the raw materials were completely converted. The reaction solution was cooled to room temperature, diluted with ethyl acetate, filtered to remove insoluble matter, and the filtrate was washed with water. The ethyl acetate layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 27 (97 mg) as a pale yellow solid in 59% yield. ESI-MS (m / z): 638.24 [MH].

[0168] Example 22 Preparation of Compound 34 [ka] Compound 1-a (120 mg, 0.162 mmol), palladium acetate (4 mg, 0.11 eq), 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl (15 mg, 0.19 eq), isopropenyl pinacol boronate (60 μL, 2 eq), dioxane (1.5 mL) and water (0.4 mL) were added to a 5 mL round-bottom single-neck flask, and the flask was filled with nitrogen gas three times, heated to 70-75°C and reacted overnight. The reaction solution was cooled to room temperature, diluted with dichloromethane, washed with water, and the organic phase was separated, dried over anhydrous sodium sulfate, filtered, concentrated and subjected to silica gel column chromatography to obtain the title compound 34 (55 mg) as a pale yellow solid in 54% yield. ESI-MS (m / z): 633.57 [MH].

[0169] Example 23 Preparation of Compound 35 [ka] Compound 1-a was reacted with methylboronic acid according to the method of Example 22 to give the title compound 35 as a pale yellow solid in 54% yield. ESI-MS (m / z): 607.38 [MH].

[0170] Example 24 Preparation of Compound 36 [ka] Compound 11 (100 mg, 0.164 mmol) was dissolved in dichloromethane (2.0 mL) and charged with pyridine (66 μL, 5 eq) and acyl chloride (27 μL, 2 eq) at ambient temperature. After the addition was complete, the reaction was allowed to proceed for 30 min at ambient temperature. TLC showed complete conversion of the starting material, and the reaction was concentrated to dryness and subjected to silica gel column chromatography to give the title compound 36 (70 mg) as an off-white solid in 65% yield. ESI-MS (m / z): 662.48 [M + H] + .

[0171] Example 25 Preparation of Compound 37 [ka] The title compound 37 was obtained by reacting compound 7 with n-pentylamine according to the method of Example 6. The compound was a pale yellow solid with a yield of 67%. ESI-MS (m / z): 706.48 [M + H] + .

[0172] Example 26 Preparation of Compound 38 [ka] Compound 1-a was reacted with cyclopropylboronic acid according to the method of Example 22 to give the title compound 38 as a pale yellow solid in 59% yield. ESI-MS (m / z): 633.38 [MH].

[0173] Example 27 Preparation of Compound 39 [ka] Oxyacanthin hydrochloride (600 mg, 0.88 mmol) was suspended in dichloromethane (8 mL), triethylamine (0.62 mL, 5 eq) was added, and the mixture was stirred in an ice bath for 5-10 min. Acryl chloride (110 μL, 1.5 eq) was added dropwise. After the addition was completed, the mixture was stirred at room temperature for 50 min. TLC showed that the raw material was completely converted, and a saturated aqueous ammonium chloride solution was added and the mixture was separated by stirring. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 39 (240 mg), which was an off-white solid, in a yield of 41%. ESI-MS (m / z): 663.2 [MH].

[0174] Example 28 Preparation of Compound 40 [ka] Under the protection of nitrogen gas, compound 8 (300 mg, 0.483 mmol) was mixed with methylmagnesium bromide (7.4 mL, 3.0 M tetrahydrofuran solution) in an ice bath, slowly warmed to room temperature, and stirred for 2-3 h. The reaction solution was poured into ice water, dichloromethane and an appropriate amount of ammonium chloride were added, and the mixture was stirred and separated. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 40 (165 mg), a pale yellow solid, with a yield of 54%. ESI-MS (m / z): 637.2 [MH].

[0175] Example 29 Preparation of Compound 41 [ka] The title compound 41 was obtained by reacting compound 7 with piperidine according to the method of Example 6. The compound was a pale yellow solid with a yield of 76%. ESI-MS (m / z): 704.68 [M + H] + .

[0176] Example 30 Preparation of Compound 43 [ka] Oxyacanthin (480 mg, 0.79 mmol) and D-biotin (240 mg, 0.98 mmol, 1.2 eq) were suspended in dichloromethane (5 mL) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (230 mg, 1.20 mmol, 1.5 eq) and 4-dimethylaminopyridine (20 mg, 0.16 mmol, 0.2 eq) were added at room temperature. After the addition was completed, the mixture was reacted at ambient temperature overnight. After the raw materials were completely converted by TLC, saturated aqueous ammonium chloride was added and the mixture was separated by stirring. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, concentrated, and subjected to silica gel column chromatography to obtain the title compound 43, an off-white solid, 435 mg, 66% yield. ESI-MS (m / z): 835.48 [MH].

[0177] Example 31 Preparation of Compound 44 [ka] Following the procedure of Example 6, compound 7 was reacted with dimethylhydroxyamine hydrochloride to give the title compound 44, which was a pale yellow solid in 78% yield. ESI-MS (m / z): 680.3 [M + H] + .

[0178] Example 32 Preparation of Compound 45 [ka] Compound 7 (452 ​​mg, 0.709 mmol) was dissolved in dichloromethane (2 mL), N,N-dimethylformamide (5.5 μL) was added, and oxalyl chloride (0.305 mL, 3.61 mmol) was added dropwise at ambient temperature. After completion of the addition, the mixture was reacted under nitrogen gas protection for 20 min. The reaction solution was then concentrated and dried, and further dissolved in dichloromethane (5 mL). At room temperature, the solution was added dropwise to a dichloromethane (5 mL) solution of aniline (0.34 mL, 3.73 mmol) and pyridine (0.28 mL, 3.46 mmol). After completion of the addition, the mixture was stirred at ambient temperature for 10 min. TLC showed that the raw material was completely converted, and a saturated aqueous ammonium chloride solution was added and stirred to separate the layers. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 45 (259 mg), which was a pale yellow solid with a yield of 51%. ESI-MS (m / z): 712.2 [M + H] + .

[0179] Example 33 Preparation of Compound 46 [ka] Under the protection of nitrogen gas, compound 44 (393 mg, 0.573 mmol) was dissolved in dried tetrahydrofuran (5 mL) and cooled to 0-5°C in an ice bath. Vinyl magnesium bromide (1.75 mL, 1.75 mmol, 3 eq, 1 M tetrahydrofuran solution) was slowly added dropwise. After the addition was completed, the mixture was reacted at ambient temperature for 1-2 h. TLC showed that the raw materials were completely converted. The reaction solution was carefully added to 1 N hydrochloric acid (5 mL) and stirred for 20 min. An aqueous solution of sodium hydroxide was added to adjust the pH to about 8. Dichloromethane was added for extraction. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 46 (290 mg, 0.449 mmol), which was a pale yellow solid with a yield of 78%. ESI-MS (m / z): 647.48 [M + H] + .

[0180] Example 34 Preparation of Compound 47 [ka] Compound 7 was reacted with 4-trifluoromethylaniline according to the method of Example 32 to give the title compound 47, which was a pale yellow solid in 58% yield. ESI-MS (m / z): 780.48 [M + H] + .

[0181] Example 35 Preparation of Compound 48 [ka] The title compound 48 was obtained by reacting compound 7 with isopropylamine according to the method of Example 6. The compound was a pale yellow solid with a yield of 59%. ESI-MS (m / z): 678.48 [M + H] + .

[0182] Example 36 Preparation of Compound 49 [ka] Following the procedure of Example 6, compound 7 and 1-adamantylamine were reacted to give the title compound 49, which was a pale yellow solid in 64% yield. ESI-MS (m / z): 770.58 [M + H] + .

[0183] Example 37 Preparation of Compound 50 [ka] The title compound 50 was obtained by reacting compound 7 with cyclobutylamine according to the method of Example 6. The compound was a pale yellow solid with a yield of 58%. ESI-MS (m / z): 690.48 [M + H] + .

[0184] Example 38 Preparation of Compound 51 [ka] The title compound 51 was obtained by reacting compound 7 with 3-aminopyridine according to the method of Example 32, as a pale yellow solid, in a yield of 71%. ESI-MS (m / z): 713.38 [M + H] + .

[0185] Example 39 Preparation of Compound 52 [ka] Compound 7 was reacted with p-methoxyaniline according to the method of Example 32 to give the title compound 52, which was a pale yellow solid in 72% yield. ESI-MS (m / z): 742.52 [M + H] + .

[0186] Example 40 Preparation of Compound 53 [ka] The title compound 53 was obtained by reacting compound 8 with cyclopropylmagnesium bromide according to the method of Example 28. The compound was a pale yellow solid with a yield of 64%. ESI-MS (m / z): 663.35 [M + H] + .

[0187] Example 41 Preparation of Compound 54 [ka] Compound 53 (183 mg, 0.28 mmol) was dissolved in dichloromethane (2 mL) and Dess-Martin Periodinane (174 mg, 0.41 mmol, 1.5 eq) was added at ambient temperature. After the addition was completed, the mixture was reacted under nitrogen gas protection for 1 h. TLC showed that the starting material was completely converted. The mixture was diluted with dichloromethane and washed once with saturated aqueous sodium bicarbonate solution. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to silica gel column chromatography to obtain the title compound 54 (38 mg, 0.057 mmol) as a pale yellow solid in 20% yield. ESI-MS (m / z): 661.28 [M + H] + .

[0188] Example 42 Preparation of Compound 55 [ka] The title compound 55 was obtained by reacting compound 7 with diethylene glycol amine according to the method of Example 6. The compound was a pale yellow solid with a yield of 61%. ESI-MS (m / z): 724.28 [M + H] + .

[0189] Example 43 Preparation of Compound 56 [ka] Following the procedure of step 2 in Example 3, compound 7 was reacted with n-pentanol to give the title compound 56 as an off-white solid in 82% yield. ESI-MS (m / z): 707.46 [M + H] + .

[0190] Example 44 Preparation of Compound 57 [ka] Compound 7 and p-fluorophenol were reacted according to the method of Example 32 to obtain the title compound 57, which was a pale yellow solid in 55% yield. ESI-MS (m / z): 731.26 [M + H] + .

[0191] Example 45 Preparation of Compound 58 [ka] Referring to the method of Step 2 in Example 3, compound 7 was reacted with diethylene glycol to obtain the title compound 58 as an off-white solid in a yield of 72%. 1 H NMR (500 MHz, chloroform-d) δ 7.70 (d, 1H), 7.34 (m, 1H), 7.02 (m, 1H), 6.94 (dd, 1H), 6.89 (dd, 1H), 6.60 (s, 1H), 6.38 (s, 1H), 6.30 - 6.29 (m, 2H), 5.49 (d, 1H), 4.50 (m, 1H), 4.42 (m, 2H), 3.78 (s, 3H), 3.77 (m, 2H), 3.70 (m, 1H), 3.63 (m, 2H), 3.61 (s, 3H), 3.58 (m, 2H), 3.47 (m, 1H), 3.29-3.05 (m, 3H), 3.17 (s, 3H), 3.02-2.67 (m, 5H), 2.77 (s, 3H), 2.60 (s, 3H), 2.55-2.26 (m, 3H).ESI-MS (m / z): 725.26 [M + H] + .

[0192] Example 46 Preparation of Compound 59 [ka] The title compound 59 was obtained by reacting oxyacanthin hydrochloride and methyl isocyanate with the method of Example 2 in a pale yellow solid with a yield of 73%. ESI-MS (m / z): 666.26 [M + H] + .

[0193] Example 47 Preparation of Compound 60 [ka] The title compound 60 was obtained by reacting oxyacanthin hydrochloride and ethyl isocyanate with the method of Example 2 in a pale yellow solid with a yield of 69%. ESI-MS (m / z): 680.28 [M + H] + .

[0194] Example 48 Preparation of Compound 61 [ka] The title compound 61 was obtained by reacting oxyacanthin hydrochloride and n-propyl isocyanate according to the method of Example 2, as a pale yellow solid, with a yield of 76%. ESI-MS (m / z): 694.24 [M + H] + .

[0195] Example 49 Preparation of Compound 62 [ka] Following the procedure of Example 2, the title compound 62 was obtained from oxyacanthin hydrochloride and isopropyl isocyanate in a yield of 70% as a pale yellow solid. ESI-MS (m / z): 694.28 [M + H] + .

[0196] Example 50 Preparation of Compound 63 [ka] Following the procedure of Example 5, compound 7 was reacted with an aqueous solution of ethylamine to obtain the title compound 63, which was a pale yellow solid with a yield of 80%. ESI-MS (m / z): 664.24 [M + H] + .

[0197] Example 51 Preparation of Compound 64 [ka] Following the procedure of Example 6, compound 7 was reacted with n-propylamine to give the title compound 64, which was a pale yellow solid in 73% yield. ESI-MS (m / z): 678.26 [M + H] + .

[0198] Example 52 Preparation of Compound 65 [ka] Following the procedure of Example 2, the title compound 65 was reacted with oxyacanthin hydrochloride and cyclopentyl isocyanate to give an off-white solid in 76% yield. ESI-MS (m / z): 720.45 [M + H] + .

[0199] Example 53 Preparation of Compound 66 [ka] Following the procedure of Example 2, the title compound 66 was reacted with oxyacanthin hydrochloride and cyclohexyl isocyanate to give an off-white solid in 71% yield. ESI-MS (m / z): 734.48 [M + H] + .

[0200] Pharmacological experiments 1) Anti-new coronavirus activity test Measurement of the inhibitory activity of compounds against the replication of SARS-CoV-2: Vero E6 cells were purchased from ATCC, and SARS-CoV-2 virus was from the National Virus Resource Center, Microbial and Toxic Species Depository Center. Vero E6 cells were cultured at 5 × 10 4The cells were cultured overnight in 48-well cell culture dishes at a density of 1000 cells / well, and the cells were pretreated with different concentrations of test samples for 1 h, and then infected with viruses (MOI: 0.01) for 1 h. The virus-compound mixture was then removed and the cells were further cultured with fresh medium containing the test samples. At 24 h pi, the cell supernatants were collected and digested in a digestion buffer, and the virus copy numbers in the cell supernatants were quantified and evaluated by quantitative real-time RT-PCR (qRT-PCR).

[0201] The results (Table 1) showed that some compounds significantly inhibited SARS-CoV-2 viral replication, and the EC 50 It was shown that all of the values ​​were obviously better than oxyacanthin hydrochloride, and were about 1 / 10 or less than that of oxyacanthin hydrochloride. This suggests that the compounds of the present invention have significantly improved inhibitory activity against coronavirus SARS-CoV-2. Furthermore, activity tests against novel coronavirus mutant strains showed that compounds 2 and 4 showed strong inhibitory activity against the delta toxin strain, and compounds 5 and 6 also showed strong inhibitory activity against the South African strain.

[0202] 2) In vitro activity test of the novel coronavirus envelope protein (2-E) ion channel Measurement of the inhibitory activity of compounds against the novel coronavirus envelope protein (2-E) ion channel: The channel activity of the purified 2-E protein was detected at room temperature using a planar lipid bilayer station (BLM). Phosphatidylcholine (PC) and phosphatidylserine (PS) stored in chloroform were mixed in a ratio of 3:2, blown dry with nitrogen gas, and dissolved in decane to a final concentration of 50 mg / ml. A cup and a tank were set in the BLM system, and the cup side was defined as the cis side and the opposite side as the trans side, and 1 ml of the inner and outer solutions were placed in each. The set device was placed on the operation table of the planar lipid bilayer station, the hole in the cup was observed with a stereomicroscope, the prepared phospholipid was applied to the cup hole, and the purified 2-E protein was placed in the cis side. The protein was inserted into the artificial lipid bilayer membrane under the drive of an electrochemical gradient and voltage. Currents were recorded in voltage clamp mode with a patch clamp amplifier, and signals were collected with Clampex 10.3 software, and the conductance and open frequency of single channels were fitted with a Gaussian function, where current open times less than 0.5-1.5 ms were considered as noise. By changing different voltages, the amplitude of currents in different conditions was recorded, and the reversal potential was observed.

[0203] When evaluating the channel inhibitory activity of a compound using the BLM system, once the appearance of a current was observed, it was recorded for three minutes, after which the test compound was added to the trans side, stirred for three seconds, and the current signal was recorded for another ten minutes to observe the change in current. Recording of the inhibition status of multiple drug concentrations and median inhibitory concentration (IC 50 When calculating IC, the current was released and recorded for 3 minutes, and then compounds were added in succession at final concentrations of 1, 10, 50, and 100 μM, and recorded continuously for 3 minutes. The inhibition of the channel at different concentrations of a specific compound was observed to determine the IC 50 was calculated.

[0204] 3) In vitro activity testing of cardiotoxicity-related targets (hERG and Nav1.5) hERG: CHO (Chinese Hamster Ovary) cells stably expressing the hERG potassium channel were used to record hERG potassium channel currents at room temperature by whole-cell patch clamp technique. Glass microelectrodes were made by extending glass electrode material (BF150-86-10, Sutter) with a puller. The tip resistance after filling with electrode solution was about 2-5 MΩ. The glass microelectrode was inserted into the amplifier probe and connected to the patch clamp amplifier. Clamp voltage and data recording were controlled and recorded through a computer by pClamp 10 software, with a sampling frequency of 10 kHz and a filter frequency of 2 kHz. After obtaining whole-cell recordings, the cell clamp was at -80 mV, and the step voltage to elicit hERG potassium currents (I hERG) was applied by depolarizing from -80 mV for 2 s to +20 mV, then repolarizing to -50 mV, maintaining for 1 s, and returning to -80 mV. This voltage stimulation was applied every 10 s, and once the hERG potassium current was confirmed to be stable (for at least 1 min), the dosing process was started. Each test concentration of compound was applied for at least 1 min, and at least two cells were measured for each concentration (n ≥ 2).

[0205] The extracellular solution consisted of (mM): 140 NaCl, 5 KCl, 1 CaCl2, 1.25 MgCl2, 10 HEPES, and 10 glucose, adjusted to pH 7.4 with NaOH. The intracellular solution formulation was (mM): 140 KCl, 1 MgCl2, 1 CaCl2, 10 EGTA, and 10 HEPES, adjusted to pH 7.2 with KOH.

[0206] Nav1.5: CHL cells stably expressing hNav1.5 sodium channels were used to record hNav1.5 sodium channel currents by whole-cell patch clamp technique at room temperature. Glass microelectrodes were made by stretching glass electrode material (BF150-86-10, Sutter) with a puller. The tip resistance after filling with electrode solution was about 2-5 MΩ. The glass microelectrode was inserted into the amplifier probe and connected to an Axopatch 200B (Molecular Devices) patch clamp amplifier. Clamp voltage and data recording were controlled and recorded through a computer by pClamp 10 software, with a sampling frequency of 10 kHz and a filter frequency of 2 kHz. After obtaining whole-cell recordings, the cell clamp was at -80 mV, and a 200 ms hyperpolarizing voltage was applied to -120 mV, followed by repolarization to -20 mV and maintained for 20 ms to elicit Nav1.5 currents. This voltage stimulation was applied every 10 s, and once the hNav1.5 sodium current was confirmed to be stable (1 min), the administration process was started. The concentrations of the test products were administered successively from the lowest experimental concentration, and each experimental concentration was administered for 1 min to reach a plateau of action, but at most for 3 min. At least three test cells were measured for each concentration of the test product (n ≥ 3), and at least two cells were measured for each concentration of the positive control product (n ≥ 2).

[0207] The extracellular solution consisted of (mM): 140 NaCl, 5 KCl, 1 CaCl2, 1.25 MgCl2, 10 HEPES, and 10 glucose, adjusted to pH 7.4 with NaOH. The intracellular solution formulation was (mM): 130 CsF, 10 NaCl, 10 EGTA and 10 HEPES, pH adjusted to 7.2 with CsOH.

[0208] 4) Cytotoxicity test In this example, the median toxic concentration (CC) of Vero E6 cells in each example was analyzed by CCK8 kit. 50 ) was confirmed. The results showed that compounds 2, 3, 4, 5, 6 and 58 had weaker cytotoxicity than oxyacanthin hydrochloride in Vero E6 cells, and their therapeutic index SI was much better than that of oxyacanthin hydrochloride (Table 1). In particular, compounds 3, 4, 6 and 58 had SI values ​​over 50, which was much higher than the other compounds. [Table 3-1] [Table 3-2]

[0209] As shown in Table 1, the compounds of the present invention, especially compounds 3, 4, 6 and 58, have IC50 values ​​of inhibition against the replication of SARS-CoV-2 original strain virus. 50 The IC value is significantly better than that of oxyacanthine hydrochloride, with a large therapeutic index and good safety. The compounds of the present invention also have good inhibitory effects on the replication of SARS-CoV-2 mutant viruses, with compounds 5 and 6 significantly inhibiting the replication of the South African mutant virus, and compounds 2 and 4 significantly inhibiting the replication of the delta mutant virus. The compounds of the present invention, especially compound 4 (IC 50 <1μM) has a good inhibitory effect on the E protein ion channel of SARS-CoV-2, and IC 50 The values ​​are significantly better than those of oxyacanthine hydrochloride. Compounds 2 and 4 also have weak activity against the hERG ion channel and Nav1.5 channel, which are highly associated with cardiotoxicity, and are expected to have less cardiac-related toxicity and side effects. Compounds 1, 2, 3, and 4 also have strong inhibitory effects on human coronavirus HCoV OC43.

[0210] 5) CD4 + T cell differentiation experiments CD4 + In vitro differentiation of T cells into Th1 CD4 + IFN-γ and Th17 CD4 in T differentiation + The content of IL-17A in T differentiation was detected, and the effects of the compounds on the Th1 / Th17 suppressive activity were studied. Testing Method: CD4+ Isolation of T cells: Mouse CD4 + CD4 T cells were isolated from the spleens of 7-8 week-old C57BL / 6 mice using a T cell sorting kit (DynabeadsR UntouchedTM Mouse CD4 Cells Isolation Kit, Invitrogen, Catalog nos: 11415D). + T cells were isolated.

[0211] CD4 + In vitro differentiation of T cells: isolated CD4 + T cells were seeded in 96-well plates and simultaneously loaded with different concentrations of compounds, corresponding cytokines and antibodies: anti-CD28 (2 μg / ml), anti-CD3 (2 μg / ml), anti-IL-4 (10 μg / ml), IL-12 (10 ng / ml), anti-IFN-γ (10 μg / ml), anti-IL-4 (10 μg / ml), IL-6 (30 ng / ml), TGF-β1 (3 ng / ml), IL-1β (10 ng / ml), IL-23 (10 ng / ml) and TNF-α (10 ng / ml). After 72 h of incubation in a 5% CO2, 37°C incubator, cells were harvested and intracellular staining was performed and flow cytometry was performed to detect the content of IFN-γ / IL-17A and the CD4 of the compounds. + The effect of T on Th1 / Th17 differentiation in vitro was evaluated. The results show that compounds 1, 2, 3, 4, 6 and 58 have strong inhibitory effects on Th1 / Th17 differentiation at a concentration of 10 μM. Compound 2 has strong inhibitory effects on Th1 / Th17 differentiation even at a lower concentration of 1 μM (Figure 1).

[0212] 6) In vivo and external anti-inflammatory test 6.1) Anti-LPS-induced inflammation in Raw 264.7 cells In this embodiment, the inflammatory factors are combined by cell vitality to analyze the effect of the compounds of the present invention on the inflammation level of Raw 264.7 cell inflammation model induced by LPS, cell vitality is analyzed by CCK-8 detection, and the mRNA expression level of inflammation-related indicators is detected by real-time quantitative PCR (Q-PCR).Raw 264.7 cells are purchased from ATCC, CCK-8 kit is purchased from Meilunbio with catalog number MA0218-3, and LPS is purchased from Sigma with catalog number L2630.

[0213] 6.1.1) Effects of compounds on cellular activity in the LPS-induced Raw 264.7 cell inflammation model Experimental method: First, Raw 264.7 cells were placed in a 96-well plate at 8000 cells / well and cultured overnight. The next day, the cells were added with 0.1% DMSO in the control group, 1 μg / ml LPS and 0.1% DMSO in the model group, and 1 μg / ml LPS and 1 μM of compounds (oxy, 1, 2, tetrandrine, tet, 3, 4, 6, 58) in the treatment group, and the 96-well plate was disinfected and then incubated in a constant temperature incubator for 16 hours. Finally, the cell viability was detected by CCK-8 kit. As shown in Figure 2, the experimental results showed that in the LPS-induced inflammation model, no damage was observed in any of the cells, and there was no difference in cell viability between the administration group and the model group, indicating that the test compound does not affect cell vitality in the LPS-induced inflammation model.

[0214] 6.1.2) Detection of mRNA levels of relevant inflammatory indicators in a Raw264.7 cell inflammation model induced by the compound LPS Experimental method: First, 5 × 10 4Raw 264.7 cells were placed in a 12-well plate at 1 cell / well and cultured overnight. The next day, 0.1% DMSO was added to the cells in the control group, 1 μg / ml LPS and 0.1% DMSO in the model group, and 1 μg / ml LPS and 1 μM of compounds (oxyacanthin hydrochloride, 1, 2, tetrandrine, tet, 3, 4, 6, 58) in the treatment group. After disinfecting the 12-well plate, the cells were incubated for 16 hours in a constant temperature incubator. Cellular mRNA was extracted by the degradation method using Trizol (YEASEN, 10606ES60), and detected by real-time quantitative PCR after reverse transcription. [Table 4]

[0215] As shown in Figure 3, the experimental results showed that induction with 1 μg / ml LPS significantly increased cytokines IL-6 and IL-1β, and chemokine CXCL9, indicating that the inflammation model was effective. When different compounds (1 μM) were administered, inflammatory factors and chemokines were lower than in the model group, and among them, compounds oxy, 1, 2, tet, 4, and 58 all had significant inhibition of different inflammatory factors, indicating that the above compounds have strong anti-inflammatory activity and are not due to an effect on cell vitality.

[0216] 6.2) Anti-TNF-α induced inflammation in Raw 264.7 cells In this embodiment, the expression level of inflammatory factors is combined with cell vitality to analyze the effect of compounds on the inflammation level of Raw 264.7 cells induced by TNF-α, cell vitality is analyzed by CCK-8 detection, and the mRNA expression level of inflammation-related indicators is detected by real-time quantitative PCR (Q-PCR).Raw 264.7 cells are purchased from ATCC, CCK-8 kit is purchased from Meilunbio with catalog number MA0218-3, and TNF-α is purchased from Merck with catalog number GF314.

[0217] 6.2.1) Effects of compounds on cellular activity in the Raw 264.7 cell inflammation model induced by TNF-α Experimental method: First, Raw 264.7 cells were placed in a 96-well plate at 8000 cells / well and cultured overnight. The next day, the cells were added with 0.1% DMSO in the control group, 10 ng / ml TNF-α and 0.1% DMSO in the model group, and 10 ng / ml TNF-α and 1 μM of compounds (oxy, 1, 2, tetrandrine, tet, 3, 4, 6, 58) in the treatment group, and the 96-well plate was disinfected and then incubated in a constant temperature incubator for 16 hours. Finally, the cell viability was detected by CCK-8 kit. As shown in Figure 4, the experimental results showed that in the TNF-α-induced inflammation model, no damage was observed in any cells, and there was no difference in cell viability between the treatment group and the model group, indicating that the test compound does not affect cell vitality in the TNF-α-induced inflammation model.

[0218] 6.2.2) Detection of mRNA levels of relevant inflammatory indicators in a Raw264.7 cell inflammation model induced by compound TNF-α Experimental method: First, 5 × 10 4 Raw 264.7 cells were placed in a 12-well plate at 1 cell / well and cultured overnight. The next day, 0.1% DMSO was added to the cells in the control group, 10 ng / ml TNF-α and 0.1% DMSO in the model group, and 10 ng / ml TNF-α and 1 μM of compounds (oxyacanthin hydrochloride, 1, 2, tetrandrine tet, 3, 4, 6, 58) in the treatment group. After disinfecting the 12-well plate, the cells were incubated for 16 hours in a constant temperature incubator. Cellular mRNA was extracted by the degradation method using Trizol (YEASEN, 10606ES60), and after reverse transcription, it was detected by real-time quantitative PCR, with the same primers as in Table 2.

[0219] As shown in Figure 5, the experimental results showed that induction with 10 ng / ml TNF-α significantly increased cytokines IL-6 and IL-1β, and chemokine CXCL9, indicating that the inflammation model was effective. When different compounds (1 μM) were administered, inflammatory factors and chemokines were reduced compared to the model group, and among them, compounds oxy, 1, 2, tet, 3, 4, 6, and 58 all had significant inhibition of different inflammatory factors. It was shown that the above compounds have strong anti-inflammatory activity, and that this is not due to an effect on cell vitality.

[0220] 6.3) In vivo experiment of acute inflammation induced by anti-LPS In this example, the effect of the compound on the LPS-induced in vivo acute inflammation model was analyzed by the expression level of inflammatory factors, the mRNA expression level of tissue inflammation-related indicators was detected by real-time quantitative PCR (Q-PCR) method, and the inflammatory factor level in serum was detected by ELISA method. C57BL / 6 mice were purchased from Shanghai SLAC Company, and the ELISA kit was purchased from Novusbio, with catalog numbers IL-6, 890860; TNF-α, 266117, respectively.

[0221] Testing Method: Solution preparation: LPS solutions were prepared in PBS at 1 mg / ml stock solution and filtered through a 0.22 μm aqueous phase filtration head, and compounds were diluted to 3 mg / ml in 85% saline + 5% DMSO + 5% HS-15 + 5% PEG400 as the solvent. Construction of inflammation model mice: C57BL / 6 mice were randomly divided into three groups, one control group with 5 experimental animals, one LPS model construction group with 5 experimental animals, and two treatment groups with 5 experimental animals. In the control group, 0.1 ml / 10 g PBS was injected intraperitoneally, and in the model group and treatment group, 3 mg / kg LPS was injected intraperitoneally and administered 2 hours later. In the control group, 0.1 ml / 10 g solvent was orally administered, and in the treatment group, 30 mg / kg compound 4 was orally administered. Blood was collected from the eye margins of each group 4 h after administration, and after euthanasia, spleen and lung tissues were collected. mRNA was extracted from lung tissue and spleen tissue, respectively, and detected by real-time quantitative PCR after reverse transcription to evaluate the mRNA expression levels of inflammation-related indicators. Serum was extracted and ELISA detection was performed to evaluate the secretion levels of inflammatory factors.

[0222] As shown in Figure 6, the experimental results showed that stimulation with 3 mg / kg LPS significantly increased cytokines and chemokines, indicating that the in vivo inflammation model is effective. Oral administration of 30 mg / kg of compound 4 significantly reduced the mRNA levels and cytokine secretion levels of inflammatory factors and chemokines compared to the model group, indicating that compound 4 has in vivo anti-inflammatory activity.

[0223] 7) Lung injury protective activity test In this example, the effects of compounds on the level of A549 pulmonary epithelial cell injury induced by TNF-α were analyzed by combining cell vitality and cell death-related molecules. The cell injury status was observed under a microscope, cell vitality was detected and analyzed by CCK-8 detection, and the mRNA expression level of injury-related indicators was detected by real-time quantitative PCR (Q-PCR). A549 cells were purchased from ATCC, CCK-8 kit was purchased from Meilunbio, catalog number MA0218-3, and LPS was purchased from Sigma, catalog number L2630.

[0224] 7.1) Effect of compounds on A549 cell activity induced by TNF-α Experimental method: First, A549 cells were placed in a 96-well plate at 8000 cells / well and cultured overnight. The next day, the cells were added with 0.1% DMSO in the control group, 10 ng / ml TNF-α and 0.1% DMSO in the model group, and 10 ng / ml TNF-α and 1 μM of compounds (oxy, 1, 2, tet, 3, 4, 6, 58) in the treatment group. After disinfecting the 96-well plate, the cells were incubated in a constant temperature incubator for 24 hours. Finally, the cell viability was detected by the CCK-8 kit. The experimental results are shown in Figure 7. In the TNF-α-induced lung injury model, in the model group, cell viability was affected and lung epithelial cells tended to die. When compared between the treatment group and the model group, some compounds could alleviate TNF-α-mediated lung epithelial cell damage, and among them, compound 1 showed a significant difference.

[0225] 7.2) Detection of mRNA levels of A549 cell damage-related indicators induced by TNF-α of the compound Experimental method: First, 5 × 10 4 A549 cells were placed in a 12-well plate at 1 cell / well and cultured overnight. The next day, 0.1% DMSO was added to the cells in the control group, 10 ng / ml TNF-α and 0.1% DMSO in the model group, and 10 ng / ml TNF-α and 1 μM of compounds (oxy, 1, 2, tet, 3, 4, 6, 58) in the treatment group. After disinfecting the 12-well plate, the cells were incubated for 24 hours in a constant temperature incubator. Cellular mRNA was extracted by the degradation method using Trizol (YEASEN, 10606ES60), and detected by real-time quantitative PCR after reverse transcription. [Table 5]

[0226] As shown in Figure 8, the experimental results showed that the inflammation model was effective, as 10 ng / ml TNF-α induced damage to lung epithelial cells and a significant increase in TNF-α and IL-1β. When different compounds (1 μM) were administered, the damage factors were reduced compared to the model group, and among them, compounds oxy, tet, 3 and 58 all had a significant inhibition of different damage factors. The compounds of the present invention have protective activity after lung epithelial cell damage, and among them, oxy, tet, 3 and 58 were shown to have strong protective activity.

[0227] 8) Anti-H2O2-induced necrotic injury in ALM12 hepatocytes In this example, the effect of the compounds of the present invention on the necrotic injury level of ALM12 hepatocytes induced by H2O2 was analyzed by microscopic morphological observation, cell vitality, and cell death-related molecules. Cell vitality was detected and analyzed by CCK-8. ALM12 cells were cultured in 1640 medium (gibco, c11995500BT) + 10% FBS (gibco, 10099141C) at 37℃ in a constant temperature incubator with 5% CO2. CCK-8 kit was purchased from Meilunbio with catalog number MA0218-3, and H2O2 was purchased from China Pharmaceutical Group Chemical Reagents Co., Ltd. with catalog number 10011208.

[0228] Experimental method: First, ALM12 cells were placed in a 96-well plate at 8000 cells / well and cultured overnight. The next day, the cells were added with 0.1% DMSO in the control group, 2 mM H2O2 and 0.1% DMSO in the model group, and 2 mM H2O2 and 1 μM of compounds (oxy, 1, 2, tet, 3, 4, 6, 58) in the treatment group, and the 96-well plate was disinfected and then incubated in a constant temperature incubator for 3 hours. Finally, the cell damage and growth were observed under a microscope, and the cell viability was detected by CCK-8 kit.

[0229] The experimental results are shown in Figure 9. In the model of liver injury induced by H2O2, the cell viability was affected and liver parenchymal cells tended to die, with a significant difference. Comparing the administration group and the model group, it can be seen that the compounds of the present invention can significantly reduce the liver cell injury mediated by H2O2 under the microscope, and the detection of cell viability shows that all the compounds can significantly protect liver cells from death.

[0230] 9) Anti-TGF-β1 induced fibrosis in A549 lung epithelial cells In this embodiment, the compound of the present invention was used to detect and analyze the alleviation effect of A549 cell fibrosis by combining microscopic observation, CCK-8 kit and Western blotting. The cell damage was observed by microscopic observation, cell vitality was detected and analyzed by CCK-8 detection, and the protein expression level of fibrosis-related indicators was detected by Western blotting. A549 cells were purchased from ATCC, CCK-8 kit was purchased from Meilunbio, catalog number MA0218-3, TGF-β1 was purchased from MCE, catalog number HY-P70543, primary antibody: collagen was purchased from ARG21965, catalog number arigobio, smooth muscle α-actin was purchased from CST, catalog number mAb#19245, VIMENTN was purchased from CST, catalog number mAb#5741, GAPDH was purchased from Yeasen, catalog number 30201ES20.

[0231] Experimental method: First, A549 cells were placed in a 96-well plate at 8000 cells / well and cultured overnight. The next day, the cells were added with 0.1% DMSO in the control group, 10 ng / ml TGF-β1 and 0.1% DMSO in the model group, and 10 ng / ml TGF-β1 and 1 μM of compounds (oxy, 1, 2, tet, 3, 4, 6, 58) in the treatment group. After disinfecting the 96-well plate, the cells were incubated in a constant temperature incubator for 72 hours. Finally, the cell damage and growth were observed under a microscope, and the cell viability was detected by CCK-8 kit.

[0232] The experimental results are shown in Figure 10 and Figure 11. After stimulating A549 cells with 10 ng / ml TGF-β1, the cells were observed under a microscope at 24 h and 72 h. After 24 hours, the A549 cells were deformed, changing from oval to elongated, indicating that fibrotic changes had occurred in the lung epithelial cells. In the treatment group, no changes were evident under the microscope. Fibrosis indicators were detected by WB, and collagen 1 and α-SMA increased in the model group, indicating that the model was effective. When the treatment group and the model group were compared, compounds oxy, 1, 2, tet and 4 could partially alleviate fibrosis, indicating that compounds oxy, 1, 2, tet and 4 could partially alleviate fibrosis indicators and have a certain degree of protective effect.

[0233] 10) Animal experiments on acute liver fibrosis induced by carbon tetrachloride In this example, the effects of the compounds of the present invention on the acute liver fibrosis model induced by carbon tetrachloride were analyzed by tissue observation, fibrosis index, HE and picrosirius red staining. The damage status of the mice was determined by body weight detection and tissue bright field photography. The protein expression level of fibrosis-related index was detected by Western blotting method. The progress of fibrosis was analyzed by HE and picrosirius red staining. C57BL / 6 mice were purchased from Shanghai SLAC, CCl4 was purchased from China Pharmaceutical Group Chemical Reagents Co., Ltd., catalog number 10006464, olive oil was purchased from China Pharmaceutical Group, catalog number 69018028, primary antibodies: collagen was purchased from ARG21965, catalog number arigobio, smooth muscle α-actin was purchased from CST, catalog number mAb#19245, VIMENTN was purchased from CST, catalog number mAb#5741, GAPDH was purchased from Yeasen, catalog number 30201ES20.

[0234] Testing Method: Solution preparation: CCl4 was diluted with olive oil (1:9, vol:vol), and compounds were prepared at a concentration of 3 mg / ml in a solvent of 85% saline + 5% DMSO + 5% HS-15 + 5% PEG400. Construction of fibrosis model mice: After 1 week of adaptation breeding, 32 C57 mice were randomly divided into 3 groups, namely, blank group, model group, and 2 treatment groups. The blank group had 6 experimental animals, and the other 3 groups had 8 experimental animals in each group. Except for the blank group, the other 3 groups were intraperitoneally injected with CCl4 (0.6 ml / kg) on ​​D1, D3, and D5, respectively, and the blank group was simultaneously intraperitoneally injected with olive oil. At the same time as the model construction, in the treatment group, the mice were intragastrically administered for 6 days and once daily, both of which were administered 2 h after CCl4 injection, and in the treatment group, 30 mg / kg of compound 2 or compound 4 was orally administered. In the blank group and model group, the mice were administered an equal amount of saline by intraperitoneal injection, and 24 h after the last administration, the mice were euthanized and the samples were left for detection. A portion of the liver tissue was cut into appropriate sizes, placed in 4% PFA, stored in a refrigerator at -80°C, and used for subsequent detection of pathological changes in tissue samples and WB detection, respectively.

[0235] Detection method: 1. After dissection, the liver was photographed in its original position. 2. Liver tissue was taken and digested with RIPA, then protein was extracted and WB detection was performed. 3. After fixation, the liver tissue was sectioned and HE stained and picrosirius red detection was performed.

[0236] Test Results: a. No animal deaths occurred until the end of the experiment, and the animal's body weight decreased on day 6 after model establishment (FIG. 12B). b. After the experimental animals were euthanized, the damage state of the mouse liver organ was observed under bright field. Fibrotic lesions were clearly observed on the surface of the mouse liver in the model group, while the roughness of the surface of the mouse liver organ in the treatment group was slightly alleviated (Figure 12A). c.HE staining showed that pseudolobules were obviously formed in the livers of the mice in the model group, and the hepatic parenchymal cells were compacted, indicating that the model was successfully constructed, and that the drug-treated group was slightly alleviated. Picrosirius red staining showed an increase in fibrous tissue in the model group, and a slight decrease in the treated group (Figure 12C). d. When liver fibrosis index was detected by WB, the fibrosis index collagen 1 and α-SMA were significantly increased in the model group, indicating that the model was successfully constructed. When 30 mg / kg of compound 2 or compound 4 was administered, a decrease in liver fibrosis index was observed (Figure 12D).

[0237] The above experimental results demonstrated that oral administration of Compound 2 or Compound 4 had some alleviating effect on acute liver fibrosis injury. As described above, in the present invention, the present inventors have disclosed for the first time a novel cyclic bisbenzyltetrahydroisoquinoline alkaloid or a pharma- ceutical acceptable salt thereof, and a method for preparing the same, which has a significant inhibitory effect on the replication of SARS-CoV-2 and inhibits EC 50 It was found that the activity of the cyclic bisbenzylisoquinoline alkaloid or its pharma- ceutical acceptable salt according to the present invention reaches the single-digit micromolar order or less. Therefore, the cyclic bisbenzylisoquinoline alkaloid or its pharma- ceutical acceptable salt according to the present invention has excellent anti-new coronavirus (SARS-CoV-2) activity and has good prospects for clinical application. Furthermore, the cyclic bisbenzylisoquinoline alkaloid or a pharma- ceutical acceptable salt thereof according to the present invention has anti-inflammatory, anti-fibrotic, and inhibitory effects on Th1 and Th17 cell differentiation, and is expected to be used for the prevention and alleviation of diseases associated with viral infection, diseases associated with inflammation (pneumonia, nonalcoholic steatohepatitis, colitis, nephritis, pancreatitis, myocarditis, arthritis, inflammatory pain), diseases associated with fibrosis (pulmonary fibrosis, silicosis, liver fibrosis, renal fibrosis, myocardial fibrosis, skin fibrosis, retinal fibrosis, bone marrow fibrosis), autoimmune diseases associated with Th1 and / or Th17 abnormal differentiation (psoriasis, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, neuromyelitis optica, myasthenia gravis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, delayed hypersensitivity reaction, graft-versus-host disease, etc.), osteoporosis, and neurodegenerative diseases.

[0238] All documents related to the present invention are incorporated herein by reference as if each document were incorporated individually. After reading the above content of the present invention, it will be understood that those skilled in the art can make various changes and modifications to the present invention, and that equivalent forms thereof are within the scope of the claims of the present invention.

Claims

1. A cyclic bisbenzyltetrahydroisoquinoline compound represented by formula I, a pharma- ceutically acceptable salt thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a crystalline hydrate thereof, a solvate thereof, or a mixture thereof, 【Chemistry 1】 In the formula: R 1 and R 2 are each independently a hydrogen atom, a halogen atom, a nitro group, a hydroxyl group, a mercapto group, C 1 ~C 6 Alkoxy group, C 1 ~C 6 Haloalkoxy group, hydroxy C 1 ~C 6 Alkoxy group, C 1 ~C 6 Alkylthio group, C 1 ~C 6 Alkyl group, C 1 ~C 6 Haloalkyl group, Amino C 1 ~C 6 Alkyl group, hydroxy C 1 ~C 6 Alkyl group, cyano C 1 ~C 6 Alkyl group, C 3 ~C 8 Cycloalkyl group, C 3 ~C 8 Cycloalkyloxy group, C 2 ~C 6 Alkenyl group, C 2 ~C 6 Alkenylcarbonyl group, C 2 ~C 6 Alkenyloxy group, C 2 ~C 6 Alkynyl group, C 2 ~C 6 Alkynyloxy group, amino group, C 1 ~C 6 Amino group substituted with an alkyl group, amino group substituted with a benzyl group, C 1 ~C 6 an amino group substituted with an alkanoyl group, 2 ~C 6 Amino group substituted with alkenylcarbonyl group, cyano group, C 1 -C 6 Carboxy group, C 1 -C 6 Aldehyde group, C 1 ~C 6 Alkanoyl group, C 3 ~C 6 Cycloalkylcarbonyl group, C 1 ~C 6 Haloalkanoyl group, sulfonylamino group, C 1 ~C 6 Sulfonylamino group substituted with an alkyl group, carbamoyl group, phenylcarbamoyl group, N-methyl-N-methoxyamino group, C 1 ~C 6 Carbamoyl group substituted with alkyl group, C 3 ~C 6 A carbamoyl group substituted with a cycloalkyl group, an adamantylcarbamoyl group, a carbamoyl group substituted with a pyridyl group or a pyrimiridyl group, a carbamoyl group substituted with a hydroxy C1-C6 alkoxy C1-C6 alkyl group, a carbamoyl group substituted with a C1-C6 alkoxy C1-C6 alkyl group, a C1-C6 alkoxycarbonyl group substituted with a hydroxy C1-C6 alkoxy group, a phenoxycarbonyl group, a hydroxymethyl group substituted with a C3-C6 cycloalkyl group, a carboxy C 1 ~C 6 Alkyl group, C 1 ~C 6 Alkylsulfonyl group, C 1 ~C 6 Haloalkylsulfonyl group, C 1 ~C 6 Amino C substituted with alkyl group 1 ~C 6 Alkyl group, C 1 ~C 20 Carbamoyloxy group substituted with alkyl group, C 3 ~C 10 A carbamoyloxy group substituted with a cycloalkyl group, 1 ~C 6 Amino C substituted with an alkanoyl group 1 ~C 6 Alkyl group, C 1 ~C 6 Alkoxycarbonyl group, carbamoyl C 1 ~C 6 Alkyl group, C 1 ~C 6 Carbamoyl C substituted with alkyl group 1 ~C 6 Alkyl group, C 2 ~C 6 Alkenylcarbonyloxy group (C 2 ~C 6 alkenyl-CO-O-), C 2 -C 10 Ester groups, 【Chemistry 2】 or -O-Z, where Z is 【Chemistry 3】 in, where n is 0, 1, 2, 3, or 4; m is 1, 2, 3, or 4; wherein the phenylcarbamoyl group and the phenoxycarbonyl group may be optionally substituted with one or more substituents selected from F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 alkoxy group, and a C1-C6 haloalkoxy group; Or, R 1 and R 2 forms a benzo [5-6 membered monocyclic heterocycle] substituted or unsubstituted with 1 to 4 substituents together with the adjacent benzene ring, and the substituents are halogen, hydroxyl group, mercapto group, oxo, thio, C 1 ~C 6 Alkyl group, C 1 ~C 6 an alkoxy group, and a cyano group, and the heterocycle contains 1 to 3 heteroatoms selected from N, O, and S; An additional condition is that the compound is: 【Chemistry 4】 A cyclic bisbenzyltetrahydroisoquinoline compound represented by formula I, a pharma- ceutically acceptable salt thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a crystalline hydrate thereof, a solvate thereof, or a mixture thereof, characterized in that it does not contain

2. R 1 and R 2 are each independently a hydrogen atom, a halogen atom, a nitro group, a hydroxyl group, a mercapto group, C 1 ~C 4 Alkoxy group, C 1 ~C 4 Haloalkoxy group, hydroxy C 1 ~C 4 Alkoxy group, C 1 ~C 4 Alkylthio group, C 1 ~C 4 Alkyl group, C 1 ~C 4 Haloalkyl group, Amino C 1 ~C 4 Alkyl group, hydroxy C 1 ~C 4 Alkyl group, cyano C 1 ~C 4 Alkyl group, C 3 ~C 6 Cycloalkyl group, C 3 ~C 6 Cycloalkyloxy group, C 2 ~C 5 Alkenyl group, C 2 ~C 5 Alkenylcarbonyl group, C 2 ~C 5 Alkenyloxy group, C 2 ~C 5 Alkynyl group, C 2 ~C 5 Alkynyloxy group, amino group, C 1 ~C 4 Amino group substituted with an alkyl group, amino group substituted with a benzyl group, C 1 ~C 4 an amino group substituted with an alkanoyl group, 2 ~C 5 Amino group substituted with alkenylcarbonyl group, cyano group, C 1 -C 4 Carboxy group, C 1 -C 4 Aldehyde group, C 1 ~C 4 Alkanoyl group, C 3 ~C 5 Cycloalkylcarbonyl group, C 1 ~C 4 Haloalkanoyl group, sulfonylamino group (-SO 2 N.H. 2 ), C 1 ~C 4 Sulfonylamino group substituted with an alkyl group (-SO 2 N.H. 2 ), a carbamoyl group (-CONH 2 ), phenylcarbamoyl group, N-methyl-N-methoxyamino group, C 1 ~C 4 Carbamoyl group substituted with alkyl group, C 3 ~C 5 A carbamoyl group substituted with a cycloalkyl group, an adamantylcarbamoyl group, a carbamoyl group substituted with a pyridyl group or a pyrimiridyl group, a carbamoyl group substituted with a hydroxy C1-C4 alkoxy C1-C4 alkyl group, a carbamoyl group substituted with a C1-C4 alkoxy C1-C4 alkyl group, a C1-C4 alkoxycarbonyl group substituted with a hydroxy C1-C4 alkoxy group, a phenoxycarbonyl group, a hydroxymethyl group substituted with a C3-C5 cycloalkyl group, a carboxy C 1 ~C 4 Alkyl group, C 1 ~C 4 Alkylsulfonyl group, C 1 ~C 4 Haloalkylsulfonyl group, C 1 ~C 4 Amino C substituted with alkyl group 1 ~C 4 Alkyl group, C 1 ~C 10 Carbamoyloxy group substituted with alkyl group, C 3 ~C 8 A carbamoyloxy group substituted with a cycloalkyl group, 1 ~C 4 Amino C substituted with an alkanoyl group 1 ~C 4 Alkyl group, C 1 ~C 4 Alkoxycarbonyl group, carbamoyl C 1 ~C 4 Alkyl group, C 1 ~C 4 Carbamoyl C substituted with alkyl group 1 ~C 4 Alkyl group, C 2 ~C 5 Alkenylcarbonyloxy group (C 2 ~C 5 alkenyl-CO-O-), C 2 -C 6 Ester groups, 【Chemistry 5】 or -O-Z, where Z is 【Chemistry 6】 where n is 0, 1, 2, 3, or 4, and m is 1, 2, 3, or 4, Or, R 1 and R 2 may form an unsubstituted or substituted benzo[5-6 membered monocyclic heterocycle] together with the adjacent benzene ring, wherein the substituents are halogen, hydroxyl, mercapto, oxo (=O), thio (=S), C 1 ~C 6 Alkyl group, C 1 ~C 6 2. The compound according to claim 1, characterized in that said heterocyclic ring contains 1 to 3 heteroatoms selected from N, O, and S.

3. R 1 and R 2 each independently represents hydrogen, fluorine, chlorine, bromine, a nitro group, a hydroxyl group, a mercapto group, a methoxy group, an ethoxy group, a trifluoromethoxy group, -SCH 3 , -SCH 2 CH 3 , propyl group, cyclopropyl group, isopropyl group, t-butyl group, trifluoromethyl group, difluoromethoxy group, bromomethyl group, chloromethyl group, vinyl group, vinylmethyl group, amino group, N-methylamino group, N-ethylamino group, N,N-dimethylamino group, N,N-diethylamino group, cyano group, carboxy group, aldehyde group, -CH 2 N.H. 2 , -CH 2 CH 2 N.H. 2 , -CH 2 OH, -CH 2 CH 2 OH, -CH 2 CN, -CH 2 CH 2 CN, formyl group, acetyl group, propionyl group, trifluoroacetyl group, sulfonylamino group, carbamoyl group, N-methylcarbamoyl group, N,N-dimethylcarbamoyl group, N-ethylcarbamoyl group, N,N-diethylcarbamoyl group, -O(C=O)NH(C4 alkyl), cyclopentylcarbamoyloxy group, cyclohexylcarbamoyloxy group, -CHCO 2 H, -CH 2 CH 2 CO 2 H, -SO 2 CH 3 , -SO 2 CF 3 , -CH 2 NHMe, -CH 2 NMe 2 , -CH 2 CONH 2 , -CONH 2 , -NHCOCH 3 , -CH 2 NHCOCH 3 , -(C=O)OCH 2 CH 2 OCH 2 CH 2 OH, -(C=O)OCH 3 , -CH 2 CONHMe, -CONHMe, -CONH(cyclopropyl), -CH 2 CONMe 2 or -O-Z, where Z is 【Chemistry 7】 where n is an integer from 0 to 4, Or, R 1 and R 2 may form an unsubstituted or substituted benzo[5-6 membered monocyclic heterocycle] together with the adjacent benzene ring, and the substituents of the substitution are halogen, hydroxyl group, mercapto group, oxo, thio, C 1 ~C 6 The compound according to claim 1, characterized in that said heterocyclic ring contains 1 to 3 heteroatoms selected from N, O and S.

4. Structure represented by formula Ia: 【Chemistry 8】 2. The compound according to claim 1, characterized in that it has the formula: (However, R 1 and R 2 is as defined in claim 1.

5. The compound of formula (I) is the following compound: 【Chemistry 9】 【Chemistry 10】 【Chemistry 11】 【Chemistry 12】 【Chemistry 13】 The compound according to claim 1, characterized in that it is selected from:

6. The compound of formula (I) is the following compound: 【Chemistry 14】 The compound according to claim 1, characterized in that it is selected from:

7. A method for producing the cyclic bisbenzyltetrahydroisoquinoline compound according to claim 1, comprising the steps of: a) using a cyclic bisbenzyltetrahydroisoquinoline containing a phenolic hydroxy group as a raw material, by alkylation reaction with an alkylating agent to obtain the cyclic bisbenzyltetrahydroisoquinoline compound; b) using a cyclic bisbenzyltetrahydroisoquinoline containing a phenolic hydroxy group as a raw material, by acylation reaction with an acylating agent to obtain the cyclic bisbenzyltetrahydroisoquinoline compound; c) reacting oxyacanthin as a raw material with a sulfonylating agent in the presence of a base to obtain compound (I-1b); (I-1b) is subjected to a coupling reaction with a coupling reagent to obtain a cyclic bisbenzyltetrahydroisoquinoline compound I-1 represented by formula I-1, and the reaction is shown in reaction scheme 1: 【Chemistry 15】 (In formula I-1, R 1 is hydrogen, halogen, C 1 ~C 6 Alkylthio group, C 1 ~C 6 Alkyl group, C 3 ~C 6 Cycloalkyl group, C 2 ~C 6 Alkenyl group, C 2 ~C 6 Alkynyl group, C 1 ~C 6 Amino group substituted with an alkyl group, amino group substituted with a benzyl group, cyano group, carboxy group, aldehyde group, C 1 ~C 6 alkanoyl groups. In formula 1-1b, L is selected from leaving groups. d) As shown in the following reaction scheme 2, oxyacanthin is used as a raw material to produce the compound of formula (I-2) through nitration, reduction and ring-closing reactions; 【Chemistry 16】 (In formula I-2, R 1 and R 2 together with the adjacent benzene ring form a benzo[5- to 6-membered monocyclic heterocycle] which is unsubstituted or substituted with 1 to 4 substituents. e) preparing the compound of formula (I-3) through a multi-step reaction using oxyacanthin as a raw material, as shown in reaction scheme 3; 【Chemistry 17】 (In formula I-3, R 1 and R 2 together with the adjacent benzene ring form a benzo[5- to 6-membered monocyclic heterocycle] which is unsubstituted or substituted with 1 to 4 substituents. f) obtaining the cyclic bisbenzyltetrahydroisoquinoline compound by converting the functional groups of the compounds obtained by methods a) to e); The method according to claim 1, further comprising:

8. 1. A pharmaceutical composition comprising: (A1) a first active ingredient comprising a therapeutically effective amount of a cyclic bisbenzyltetrahydroisoquinoline compound represented by formula I according to any one of claims 1 to 6, its enantiomers, diastereomers, racemates, and pharma- ceutically acceptable salts, crystalline hydrates, and solvates thereof, or a mixture thereof; and (B) A Pharmaceutically Acceptable Carrier The pharmaceutical composition comprising:

9. Use of the cyclic bisbenzyltetrahydroisoquinoline compound according to any one of claims 1 to 6 or the drug composition according to claim 8, characterized in that the use is for the manufacture of an inhibitor of viral replication suppression, anti-inflammation, anti-fibrosis, and T cell differentiation suppression, and / or for the manufacture of a drug for preventing and / or treating diseases associated with viral infection, diseases associated with inflammation / fibrosis (such as pulmonary fibrosis, silicosis, hepatic fibrosis, non-alcoholic steatohepatitis, renal fibrosis, myocardial fibrosis, dermal fibrosis, retinal fibrosis, bone marrow fibrosis, etc.), autoimmune diseases associated with abnormal differentiation of Th1 and / or Th17 (such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, neuromyelitis optica, etc.), osteoporosis, inflammatory pain, or neuroprotective drugs.

10. 10. The use according to claim 9, characterized in that the virus is a coronavirus selected from the following group: human coronaviruses, severe acute respiratory syndrome coronavirus (SARS-CoV), 2019 novel coronavirus and its variants (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), coronaviruses leading to the common cold, or a combination thereof.

11. 10. The use according to claim 9, characterized in that the disease is pulmonary fibrosis, silicosis, liver fibrosis, non-alcoholic steatohepatitis, renal fibrosis, myocardial fibrosis, skin fibrosis, retinal fibrosis, bone marrow fibrosis, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, neuromyelitis optica, osteoporosis, inflammatory pain, neurodegenerative diseases or a combination thereof.

12. The use according to claim 9, characterized in that the related disease caused by a viral infection is selected from the group consisting of common cold, high-risk symptom infection, respiratory infection, pneumonia and its complications caused by human coronavirus, Corona Virus Disease 2019 (COVID-19) caused by SARS-CoV-2, novel coronavirus epidemic caused by SARS-CoV-2, or a combination thereof.

13. The use according to claim 9, characterized in that it is for the manufacture of (a) an inhibitor that suppresses the replication of the 2019 novel coronavirus (SARS-CoV-2) and / or (b) a drug for treating and / or preventing or alleviating associated diseases caused by infection with the 2019 novel coronavirus and its mutant strains (SARS-CoV-2).

14. The use according to claim 9, characterized in that it is for the manufacture of a drug for treating and / or preventing or alleviating inflammation, fibrosis and associated diseases caused by abnormal T cell differentiation.

Citation Information

Patent Citations

  • Novel use of vinetine and analogue thereof

    CN101371840A

  • Bisbenzylisoquinoline derivative

    JP1990111777A

  • Oxyacanthin-containing cosmetic or pharmaceutical, especially dermatological, compositions specifically intended for stimulating hair growth or inhibiting hair loss

    JP1994505750A

  • NF-kappa b activity inhibitor

    JP1999180873A

  • Pharmaceutical composition containing plant-derived alkaloid

    JP2021075469A